

A Review on Analytical Methods of Antigout Agents

Abstract

The aim of this study was to provide information of the development in analytical perspective of impurity profiling, force degradation, and bioanalysis of pharmaceutical drug substance and drug products used for the treatment of gout. This information was discussed on the basis of year of publication, matrix (active pharmaceutical ingredient, dosage form, and biological fluid), sample preparation technique, column and types of elution in chromatography (isocratic or gradient), detector, and therapeutic categories of drug, which were used for analysis. It focuses mainly on analytical methods including hyphenated techniques for the identification and quantification of impurity, degradants, and metabolites in different pharmaceutical and biological matrices.

Keywords: Bioanalysis and antigout drug, forced degradation study, impurity profiling

Introduction

Development of analytical methods and validation play an important role in the drug discovery, development, and manufacturing of pharmaceuticals. The number of drugs introduced into the market may be either new entities or partial structure modification of the existing one. There is a time lag from the date of introduction of a drug into the market to the date of its inclusion in pharmacopoeias due to possible unpredictability in the continuous and wider uses of such drugs, reports of new toxicities (resulting in their withdrawal from the market), development of patient resistance, and introduction of better drugs by competitors. Under such conditions, standard and analytical procedure of such drugs may not be available in the pharmacopoeias. Therefore, there is a scope to develop newer analytical methods for such drug. The choice of analytical methodology is based on many considerations such as chemical properties of the analyte and its concentration, sample matrix, the speed and cost of analysis, type of measurement, that is, quantitative or qualitative, and the number of samples. Analytical methods are used to perform identification tests, potency of assays, quantitative tests for impurities, limit test for the control of impurities, specific test (particle size analysis, X-ray diffraction, etc.), and quantitative determination of drugs

and metabolites in biological matrices such as blood, serum, plasma, urine, and tissues.^[1]

Analytical methods are intended to establish the identity, purity, physical characteristic, and potency of the drugs that we use. Methods may also support safety and characterization studies or evaluation of drug performance. Safety and efficacy of pharmaceutical product are fundamental aspects in drug therapy and these are dependent not only on the intrinsic toxicological properties of active ingredient but also on the impurities and degradation product that it may contain. The impurity profile of drug is an important in case of manufacturing of high purity drug. The degradation products may be provided through forced degradation studies, which provides information about possible degradation routes, evaluation of the factors that may interfere in the drug stability and critical analysis of the drug degradation profile. Bioanalysis is also an essential part in toxicological evaluation, pharmacokinetic (PK) and pharmacodynamic (PD) studies during drug development.^[2]

Impurity profile

Impurity is any component of the new drug substance that is not the chemical entity, which is defined as the new drug substance, and impurity profile is a description of the identified and unidentified impurities present in new drug substance.^[3-9] Various terms that have been commonly used to describe impurities are as follows:

- By-product
- Degradation product

How to cite this article: Kachave RN, Mandlik PB, Wakchaure SR. A review on analytical methods of antigout agents. J Rep Pharm Sci 2020;9:136-67.

Ramanlal N. Kachave,
Pragati B. Mandlik¹,
Snehal R. Wakchaure¹

Departments of Pharmaceutical Chemistry and ¹Pharmaceutical Quality Assurance, Amrutvahini College of Pharmacy, Sangamner, Maharashtra, India

Received: 10 Apr 2019

Accepted: 28 Sept 2019

Published: 26 Jun 2020

Address for correspondence:

Dr. Ramanlal N. Kachave,
Department of Pharmaceutical Chemistry, Amrutvahini College of Pharmacy, Sangamner 422608, Maharashtra, India.
E-mail: ramanlalkachave26@gmail.com

Access this article online

Website:
www.jrpsjournal.com

DOI:10.4103/jrpts.JRPTPS_32_19

Quick Response Code:



This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

Archive of SID

- Interaction product
- Intermediate
- Penultimate intermediate
- Related product
- Transformation product

Classification of impurities

1. Organic impurities: They arise during the manufacturing process and/or storage of the new drug substance. They can be identified or unidentified, volatile or nonvolatile, and include the following:
 - Starting materials
 - By-products
 - Intermediates
 - Degradation products
 - Reagents, ligands and catalysts
2. Inorganic impurities: They can result from the manufacturing process. They are normally known and identified and include the following:
 - Reagents, ligands, and catalysts
 - Heavy metals or other residual metals
 - Inorganic salts
 - Other materials (e.g., filter aids and charcoal)
3. Residual solvents: They are inorganic or organic liquids used as vehicles for the preparation of solutions or suspensions in the synthesis of new drug substance. As these are generally of known toxicity, the selection of appropriate controls is easily accomplished.

Elemental impurity

Elemental impurities^[7] in drug products may arise from several sources; they may be residual catalysts that were added

intentionally in synthesis or may be present as impurities (e.g., through interactions with processing equipment or container/closure systems or by being present in components of the drug product). Because elemental impurities do not provide any therapeutic benefit to the patient, their levels in the drug product should be controlled within acceptable limits.

Classification of elemental impurity is as following:

Class 1: As, Cd, Hg, and Pb

Class 2A: Co, Ni, and V

Class 2B: Ag, Au, Ir, Os, Pd, Pt, Rh, Ru, Se, and Tl

Class 3: Ba, Cr, Cu, Li, Mo, Sb, and Sn

Other: Al, B, Ca, Fe, K, Mg, Mn, Na, W, and Zn

International Conference on Harmonization guidelines

- Q1A (R) Stability testing of new drug substance and products
- Q3A (R) Impurities in drug substance
- Q3B Impurities in drug product
- Q3C Impurities: residual solvent
- Q3D Elemental impurities
- Q6A Specification

According to International Conference on Harmonization (ICH) guidelines on impurities in new drug products, identification of impurities below 0.1% level is not considered to be necessary, unless potential impurities are expected to be unusually potent or toxic [Table 1] [Figure 1].

Forced degradation study

Forced degradation studies^[10-14] are used to facilitate the development of analytical methodology, to gain a better

Table 1: Thresholds according to International Conference on Harmonization Q3A (R2)

| Maximum daily dose | Reporting threshold | Identification threshold | Qualification threshold |
|--|---------------------|---|---|
| ≤2 g/day | 0.05% | 0.10% or 1 mg per day intake (whichever is lower) | 0.15% or 1 mg per day intake (whichever is lower) |
| >2 g/day | 0.03% | 0.05% | 0.05% |
| Thresholds for degradation products in new drug products | | | |
| Reporting thresholds | | | |
| Maximum daily dose | | Threshold | |
| ≤1 g | | 0.1% | |
| >1 g | | 0.05% | |
| Identification thresholds | | | |
| Maximum daily dose | | Threshold | |
| <1 mg | | 1.0% or 5 µg TDI, whichever is lower | |
| 1–10 mg | | 0.5% or 20 µg TDI, whichever is lower | |
| >10–2 mg | | 0.2% or 2 mg TDI, whichever is lower | |
| >2 g | | 0.10% | |
| Qualification thresholds | | | |
| Maximum daily dose | | Threshold | |
| <10 mg | | 1.0% or 50 µg TDI, whichever is lower | |
| 10–100 mg | | 0.5% or 200 µg TDI, whichever is lower | |
| >100 mg–2 g | | 0.2% or 3 mg TDI, whichever is lower | |
| >2 g | | 0.15% | |

TDI = Therapeutic drug impurity




Figure 1: Schematic representation of scheme for impurity profiling of drugs^[6]

understanding of drug substance and drug product stability, and to determine degradation pathways and degradation products. This study will help to generate the most stable formulation. The stability of drug product and drug substance is a critical parameter, which may affect purity, potency, and safety. Changes in drug stability can risk patient safety by formation of toxic degradation product or products or deliver lower dose than expected. Forced degradation study chart is shown in Figure 2. The ICH addresses the questions relating to stability as follows:

- Q1A (R2): Stability testing of new drug substances and products
- Q1B: Photostability testing of new drug substances and products
- Q1C: Stability testing for new dosage form
- Q1D: Bracketing and matrixing designs for stability testing of new drug substances and products
- Q1E: Evaluation for stability data

Bioanalysis

Bioanalysis^[16,17] is covering the identification and quantification of analytes in biological samples (blood, plasma, serum, saliva, urine, feces, hair, and organ tissue). Bioanalysis has an important role to perform toxicokinetic (TK), PK, and PD studies of new drugs. Bioanalytical method development is one of the bottlenecks for drug development, and validation is crucial for the quantitative determination of various types of


analytes in biological matrices. Bioanalysis is also established in clinical, preclinical, and forensic toxicology laboratories. It is an important discipline in many research areas such as development of new drug, forensic analysis, doping control, and identification of biomarker for the diagnosis of many diseases.

The bioanalysis procedure includes sampling, sample preparation, analysis, calibration, and data evaluation. Sample preparation has an important role in bioanalysis to get clean extract with high extraction efficiency. Regularly used sample preparation methods are protein precipitation, liquid-liquid extraction (LLE), solid phase extraction (SPE), supercritical fluid extraction, and matrix solid phase extraction (MSPE). Microextraction techniques are also there and these are solid phase microextraction (SPME), stir bar sorptive extraction (SBSE), and microextraction by packed sorbent. After sample preparation, separation and detection are performed with the help of different analytical techniques.

Gout

Gout is a common metabolic disorder caused by high uric acid levels and marked by episodic deposition of uric acid crystal in joints and other tissues such as the kidney. Gout affects around 1%–2% of the Western population at some point in their lifetime and is becoming more common. Some 5.8 million people were affected in 2013. Rates of gout approximately doubled between 1990 and 2010. This rise is believed to be due to increasing life expectancy, changes in diet, and an

Archive of SID

Figure 2: Forced degradation study^[15]

increase in diseases associated with gout such as metabolic syndrome and high blood pressure. These antigout agents have some major side effects such as headaches, dizziness, rashes, aggravation of asthma, heart and kidney problem, and increased blood pressure. These side effects are associated with drug substance, but these may be due to the presence of impurities or degradants.^[18] Force degradation study provides very valuable information with respect to the stability of drug formulations during their life cycle.^[15] So to avoid such side effects and to maintain quality and purity of both drug substance and drug product, impurity profiling, force degradation, and bioanalysis study of antigout drug are important and it was discussed and summarized in Tables 2 and 3.

Category-wise analytical perspectives of antigout drug

Various drugs from different classes of antigout drugs were studied for impurity profiling, force degradation, and bioanalysis. The study was based on the following analytical perspectives:

- Categories: Antigout drugs fall into variety of categories such as nonsteroidal anti-inflammatory drug (NSAID), steroids, microtubule inhibitor, uricosuric drug, and uric acid synthesis inhibitor. Impurity profile, force degradation study, and bioanalysis study are carried out on the drug belonging to these categories [Figure 3].
- Matrix: Maximum work is carried out on active pharmaceutical ingredient (API) followed by tablet and capsule. Other dosage forms such as suppository, ophthalmic, and topical preparation are used for impurity profiling and force degradation study [Figure 4].

For bioanalysis study, different species are used as shown in Figure 5. Plasma is widely used in bioanalytical method development. Other biological fluids such as urine, serum, aqueous humor, saliva, synovial fluid, and bile are also used [Figure 6].

- Column: Columns are one of the most important parts of chromatographic technique where separation of analyte is performed. Column dimensions, chemistry of column, nature of stationary phase filled in column, and particle size of stationary phase are important parameters for the separation of different components from a mixture. C₁₈ columns are widely used column, whereas other C₈, phenyl, cyano, and silica are used wherever they are suitable [Figure 7].
- Types of elution: Isocratic elution has used in greater amount as compared to isocratic elution [Figure 8].
- Detectors: Ultraviolet (UV) and mass detector are widely used. Photo diode array (PDA) and fluorescence detector are less used [Figure 9].

Force Degradation and Impurity Study

Acute gout

Nonsteroidal anti-inflammatory drug

Naproxen: Maher *et al.*^[19] developed a simple and sensitive stability indicating HPLC-DAD method for determination of Diflunisal and naproxen. The response surface of diflunisal (DFL) and naproxen (NAP) was constructed by the artificial neural network model. No degradation was observed under the thermal conditions.

Habib *et al.*^[20] developed two chromatographic methods for the determination of DFL and NAP in their binary mixture and in the presence of DFL toxic impurity, biphenyl-4-ol. First method was thin layer chromatography-densitometry and second was HPLC-DAD method. They were statistically compared with the reported method using Student's *t*-test and *f*-test; no significant difference was obtained.

Reddy *et al.*^[21] reported a simple, rapid, gradient reverse-phase ultra-performance liquid chromatography (RP-UPLC)

Table 2: Representative chromatographic analytical methods of impurity and forced degradation profiling of antigout drugs

| Sr. no. | Name of drug | API/dosage form | Impurity/degradant | Stationary phase | Mobile phase | Detection | Year |
|---------------|---|---------------------|---|---|--|------------|------|
| 1. Acute gout | | | | | | | |
| A. NSAID | | | | | | | |
| 1 | Naproxen (i) Maher | Tablet | 1 Impurity | Eclipse XDB ss C18 (150 × 4.6 mm, 5 µm) | 0.05 M sodium dihydrogen phosphate (pH 3.4):ACN (50:50 vol/vol) | DAD | 2013 |
| | | | | Zorbax Eclipse C18 (250 × 4.6 mm, 5 µm) | Methanol:water (pH 4 with OPA) (55:45 vol/vol) | DAD | 2015 |
| | | | | Acquity BEH C18 column (100 × 2.1 mm, 1.7 µm) | 0.1% OPA (pH 3):ACN (gradient) | UV 230 nm | 2016 |
| | | | | Kromasil CelluCoat chiral column | Hexane:isopropanol:TFA (90:9.9:0.1 vol/vol/vol) | DAD | 2017 |
| 2 | Indomethacin (i) Kwong <i>et al.</i> | Capsule suppository | 2 Impurities in capsule and 2 impurities in suppository | C18 column (4.6 mm × 25 cm, 5 µm) | Methanol:water:acetonitrile:acetic acid (55:35:10:1 vol/vol/vol/vol) | UV 234 nm | 1981 |
| | | | | Zorbax phenyl analytical column (75 × 4.6 mm, 3.5 µm) and Zorbax SB-CN (150 × 4.6 mm, 5 µm) | Acetonitrile:0.2% phosphoric acid (50:50 vol/vol) | UV 237 nm | 2004 |
| | | | | Sinergy Hydro RP 18 (250 × 4.6 mm, 4 µm) | Solvent A, Milli-Q water | PDA | 2011 |
| | | | | Lichrosphere RP C18 (250 × 4.0 mm, 5 µm) | Solvent B, Methanol:ACN (1:1 vol/vol) Ethyl acetate (100%) | UV 318 nm | 2013 |
| 3 | Piroxicam (i) Bartsch <i>et al.</i> | API | 6 Degradants | Lichrosphere RP C18 (119 × 3 mm, 5 µm) | Methanol:0.4 M acetate buffer (pH 4.3) (45:55 vol/vol) | DAD | 1999 |
| | | | | SUPELCO C18 (125 × 4 mm, 5 µm) | Methanol:phosphate buffer (pH 2.5) (80:20 vol/vol) | UV 245 nm | 2002 |
| 4 | Diclofenac (i) Hajkova <i>et al.</i> | Topical emulgel | 1 Degradant | Kromasil C18 (5 µm) | Methanol:0.1% aqueous formic acid (pH 2.5) (80:20 vol/vol) | UV 254 nm | 2005 |
| | | | | Alltima silica column (250 × 4.6 mm, 10 µm) | Acetic acid:ethanol:ethyl acetate:chloroform (1:4:100:400 vol/vol/vol/vol) | DAD 280 nm | 2010 |
| 5 | Sulindac (i) Krier <i>et al.</i> | API | 3 Impurities | | | | |

Table 2: Continued

| Sr. no. | Name of drug | API/dosage form | Impurity/degradant | Stationary phase | Mobile phase | Detection | Year |
|---------|---|-----------------------|-------------------------|--|---|-----------|------|
| 6 | B. Steroids Corticosteroids (i) Hymer | API | 3 Impurities | Hypersil ODS (250 × 4.6 mm, 5 µm) | Solvent A, acetonitrile:water (15:85 vol/vol) Solvent B, acetonitrile:water (50:50 vol/vol) (gradient) Water:acetonitrile:acetic acid (70:30:1 vol/vol/vol) | UV 245 nm | 2004 |
| | | | | | | | |
| | | | | | | | |
| 7 | (ii) Lu <i>et al.</i> | API | 32 Potential impurities | ACE C18 (150 × 4.6 mm, 3 µm) | DAD 254 nm | 2010 | |
| | | | | | | | |
| 8 | Prednisolone (i) Marley <i>et al.</i> | Ophthalmic suspension | 8 Impurities | Agilent Poroshell C18 (100 × 4.6 mm, 2.7 µm) | Solvent A, acetonitrile:water (10:90 vol/vol) Solvent B, acetonitrile (gradient) | UV 254 nm | 2014 |
| | | | | | | | |
| | | | | | | | |
| 9 | Triamcinolone (i) Matysová <i>et al.</i> | Topical cream | 1 Impurity | SUPELCO C18 (125 × 4 mm, 5 µm) | Acetonitrile:water (40:60 vol/vol) | 240 nm | 2003 |
| | | | | | | | |
| | | | | | | | |
| 9 | II. Chronic gout A. Uric acid synthesis inhibitor Febuxostat (i) Kadirav <i>et al.</i> | API | 4 Impurities | Kromacil C18 (150 × 4.6 mm, 5 µm) | Solvent A, 0.01 M aqueous ammonium acetate (pH 3.5):trifluoroacetic acid Solvent B, acetonitrile (gradient) | ESI-MS | 2011 |
| | | | | | | | |
| | | | | | | | |

ACN = Acetonitrile; OPN = Ortho phosphoric acid

Table 3: Analytical methods of bioanalysis of antigout drugs

| Sr. no. | Analyte | Matrix (species) | Stationary phase | Mobile phase | Detector | Year |
|---------|---------------------------------------|-------------------------------------|---|--|--|------|
| 1 | I. Acute gout A. NSAID Naproxen | | | | | |
| | (i) Loenhout <i>et al.</i> | Plasma and urine (human) | Lichrosorb RP C8 | Methanol: citrate buffer (pH 6.5) (50:50 vol/vol for plasma and 40:60 for urine). Flow rate 1.5 mL/min | UV 254 nm, FLU Ex = 235 nm, Em = 350 nm | 1982 |
| | (ii) Wanwimolruk | Plasma (human) | Hypersil C18 (100 × 2 mm, 5 µm) | ACN: 10 mM phosphate buffer (pH 2.5) (40:60 vol/vol) | FLU Ex = 225 nm Em = 350 nm | 2006 |
| | (iii) Karidas <i>et al.</i> | Plasma and urine (human) | Spherisorb C18 (250 × 4.5 mm, 5 µm) | ACN: 0.1 M sodium acetate (pH 6.4 by glacial acetic acid) (35:15 vol/vol), flow rate 2.2 mL/min | UV 278 nm | 2006 |
| | (iv) Mikami <i>et al.</i> | Urine (human) | Wakosil C18 (150 × 4.6 mm, 5 µm) | ACN: water: triethylamine (pH 3 adjusted by phosphoric acid) (500:500:1 vol/vol/vol) | UV nm FLU Ex = 280 nm Em = 350 nm | 2000 |
| | (v) Elsinghorst <i>et al.</i> | Plasma (human) | Betasil C18 (50 × 4.6 mm, 5 µm) | 0.02 M ammonium acetate buffer (pH 4): ACN (30:70 vol/vol) flow rate 1 mL/min | ESI-QqQ | 2011 |
| | (vi) Patel | Plasma (human) | Acquity BEH C18 (50 × 2.1 mm, 1.7 µm) | Methanol: acetonitrile: 4.0 mM ammonium acetate | ESI-MS | 2012 |
| | (vii) Almadhi and Bapirzadeh | Plasma (human) | Eurosphere C18 (250 × 4 mm, 5 µm) | ACN: 0.05 M phosphate buffer (pH 2.6) (65:35 vol/vol), flow rate 1 mL/min | UV 230 nm | 2013 |
| | (viii) Shi <i>et al.</i> | Plasma (rat) | Synergi fusion RP C18 (50 × 3 mm, 4 µm) | 0.1% Formic acid aqueous solution: methanol (28:72 vol/vol), flow rate 0.5 mL/min | ESI-MS | 2014 |
| | Indomethacin | | | | | |
| | (i) Terweij-Groen <i>et al.</i> | Serum and urine | Zorbax ODS (250 × 4.6 mm, 5 µm) | Ethanol: <i>n</i> -butanol: aqueous buffer (gradient) | UV 235 nm | 1979 |
| 2 | (ii) Bernstein and Evans | Urine and plasma | C18 column (25 cm × 4.6 mm, 10 µm) | ACN: acetic acid (flow rate 1.5 mL/min for urine sample and 2 mL/min for plasma sample) | UV 285 nm FLU Ex = 288 nm Em = 390 nm | 1981 |
| | (iii) Shimek <i>et al.</i> | Plasma (human) | Zorbax ODS (25 cm × 4.6 mm) | Methanol: acetate buffer (gradient) | UV 254 nm | 1982 |
| | (iv) Greizerstein and Mclaughlin | Blood (rat) | Bondapak C18 (30 cm × 4 mm) | Methanol in water 66% vol/vol Flow rate 2 mL/min | UV | |
| | (v) Smith and Benet | Urine (human) | RP C8 (150 × 4 mm, 5 µm) | ACN: 0.025 M sodium acetate (pH 4) (22:78 vol/vol) flow rate 2 mL/min | UV 254 nm FLU Ex = 305 nm Em = 370 nm | 1983 |
| | (vi) De Zeeuw <i>et al.</i> | Renal PST (rabbit) | µBondapak C18 (30 cm × 2 mm, 10 µm) | Methanol: water (52:48 vol/vol) | UV 254 nm FLU Ex = 295 nm Em = 376 nm | 1986 |
| | (vii) Sauvair <i>et al.</i> | Plasma (Wistar rat and Beagle dogs) | Bondapak C18 (10 cm × 8 mm, 10 µm) | ACN: 0.01 M acetic acid in water (70:30 vol/vol) flow rate 1.5 mL/min | UV 250 nm | 1986 |

Table 3: Continued

| Sr. no. | Analyte | Matrix (species) | Stationary phase | Mobile phase | Detector | Year |
|---------|---------------------------|------------------------------------|--|--|---------------------------------------|------|
| (viii) | Stubbs <i>et al.</i> | Urine and plasma (human) | Sepralyte C18 (5 cm × 4.6 mm, 3 µm) | 0.05 M Ammonium dihydrogen phosphate (pH 3.5 by 0.01 M phosphoric acid):methanol (42:58 vol/vol) | UV FLU Ex = 295 nm Em = 372 nm | 1986 |
| (ix) | Brown <i>et al.</i> | Serum (human) | Nova Radial-Pak C18 RP column | ACN:water:acetic acid (54.2:45.2:0.6) | UV detected 254 nm | 1988 |
| (x) | Kim <i>et al.</i> | Serum (Beagle dog) | RP-NOVA-PAK C18 (3.9 mm i.d. × 150 mm) | 0.5 M Acetate buffer (pH 4):methanol (7:3 vol/vol) | FLU Ex = 278 nm Em = 358 nm | 1988 |
| (xi) | Avgerinos and Malamataris | Plasma and urine (human) | Spherisorb (25 cm × 4.5 mm, 5 µm) | ACN:0.1 M sodium acetate (35:65 vol/vol) flow rate 2.5 mL/min | UV 258 nm | 1989 |
| (xii) | Hubert <i>et al.</i> | Plasma | LichroCART C18 (125 × 4 mm) | Methanol:phosphate buffer (pH 7.4) (60:40 vol/vol) flow rate 0.7 mL/min | UV 254 nm | 1989 |
| (xiii) | Mawatari <i>et al.</i> | Serum (human) | Unisil C18 (150 × 4.6 mm, 5 µm) | 0.07 M phosphate buffer (pH 6.6):ACN (65:35) flow rate 1 mL/min | FLU Ex = 358 nm Em = 462 nm | 1989 |
| (xiv) | Singh <i>et al.</i> | Plasma and urine (horse) | Supelcosil C8 (7.5 cm × 4.6 mm, 3 µm) | Phosphoric acid:ACN (55:45 vol/vol) flow rate 1 mL/min | DAD FLU Ex = 235 nm Em = 405 nm | 1991 |
| (xv) | Caturla and Cusido | Plasma (human and race horse) | Ultrasphere ODS (150 × 4.6 mm, 5 µm) | 0.02 M ammonium sulfate:ACN (45:55 vol/vol) | UV 340 nm | 1992 |
| (xvi) | Kubo <i>et al.</i> | Serum | Inertsil ODS (150 × 4.6 mm, 5 µm) | 30 mM H ₂ O ₂ | FLU Ex = 358 nm Em = 462 nm | 1993 |
| (xvii) | Vree <i>et al.</i> | Plasma and urine (human) | Spherisorb ODS (250 × 4.6 mm, 5 µm) | ACN:phosphoric acid (gradient) | UV 254 nm | 1993 |
| (xviii) | Niopas and Mamzoridi | Plasma (human) | Vydacss analytical column (250 × 4.6 mm, 5 µm) | 10 mM phosphoric acid:ACN (40:60 vol/vol) flow rate 0.9 mL/min | UV 280 nm | 1994 |
| (xix) | Sato <i>et al.</i> | Plasma (human) | Lichrosorb RP 18 (250 × 4, 7 µm) | 6 mM phosphoric acid:ACN (50:50 vol/vol) flow rate 2 mL/min | UV 205 nm | 1996 |
| (xx) | Liu <i>et al.</i> | Plasma (rat) | Zorbax Eclipse C18 (250 × 4.6 mm) | Methanol:0.1% phosphoric acid (70:30 vol/vol) flow rate 1 mL/min | UV 254 nm | 2001 |
| (xxi) | Dawidowicz <i>et al.</i> | Plasma (human) | Prodigy C18 (150 × 4.6 mm, 5 µm) | ACN:water (63:37 vol/vol) flow rate 0.8 mL/min | UV | 2009 |
| (xxii) | Michael and Moneeb | Urine (human) | Zorbax C8 (250 × 4.6 mm, 5 µm) | 10 mM Acetate buffer (pH 4):methanol (60:40 vol/vol) flow rate 1.5 mL/min | DAD | 2011 |
| (xxiii) | Liu <i>et al.</i> | Plasma, urine, and tissue (rabbit) | Diamonsil C18 (150 × 4.6 mm, 5 µm) | Methanol:ACN:water:formic acid (45:45:10:0.5 vol/vol/vol/vol) | ESI-QqQ | 2011 |
| (xxiv) | Wang <i>et al.</i> | Plasma and urine (human) | Symmetry C18 (150 × 4.6 mm, 5 µm) | 0.05% Formic acid aqueous solution:ACN (47:53 vol/vol) flow rate 1 mL/min | ESI-MS | 2013 |
| (i) | Piroxicam | Plasma (human) | Bondpack cyano column (300 × 3.9 mm, 10 µm) | ACN:water:acetic acid (25:70:5 vol/vol/vol) flow rate 1.2 mL/min | UV 365 nm | 1980 |
| (ii) | Dixon <i>et al.</i> | Plasma (human) | Lichrosorb RP C18 (150 × 3.2 mm, 5 µm) | ACN:water:0.1 M phosphate buffer (pH 5) (30:30:40 vol/vol/vol) | UV 361 nm | 1984 |

Table 3: Continued

| Sr. no. | Analyte | Matrix (species) | Stationary phase | Mobile phase | Detector | Year |
|----------------------------------|------------|---------------------------------|---|--|-----------------------------------|------|
| (iii) Richardson and Ross | | Plasma and urine (human) | For plasma: μ Bondpack CN column (15 cm \times 3.9 mm, 10 μ m), and for urine: μ Bondpack C18 (30 cm \times 3.9 mm, 10 μ m) | For plasma: 50 mM Na ₂ H ₂ Pb ₄ in acetonitrile:water (25:75 vol/vol) (pH 3.2) For urine sample: 5 mM sodium sulfonate buffer:tetrahydrofuran:glacial acetic acid (54:45:1 vol/vol) flow rate 1.5 mL/min for both 0.05 M pot. dihydrogen phosphate (pH 2.2):methanol (65:35 vol/vol) flow rate 0.5 mL/min 0.04 M Phosphate buffer (pH 8):methanol (60:40 vol/vol) flow rate 1.2 mL/min | UV 365 nm | 1986 |
| (iv) Macek and Vacha | | Plasma (human) | Separon CN (15 cm \times 3.3 mm, 5 μ m) | | UV 360 nm | 1987 |
| (v) Boudinot and Ibrahim | | Plasma (human) | Econosphere ODS (25 cm \times 4.6 mm, 5 μ m) | | UV | 1988 |
| (vi) Milligan | | Plasma, urine, and bile (human) | Techsil C10 CN column (20 cm \times 3.9 mm, 10 μ m) | Acetonitrile:water (pH 3.5) (22:78 vol/vol) | UV 365 nm | 1991 |
| (vii) Cerretani <i>et al.</i> | | Plasma, muscle, and skin (rat) | Novapak C18 (15 cm \times 3.9 mm, 3 μ m) | THF:water (45:55 vol/vol) flow rate 0.7 mL/min | UV 313 nm | 1992 |
| (viii) Avgerinos <i>et al.</i> | | Plasma and urine (human) | Spherisorb C18 (25 cm \times 4.5 mm, 5 μ m) | ACN:0.1 M sodium acetate (pH 3.3 by glacial acetic acid) (33:67 vol/vol) flow rate 2.5 mL/min | UV 330 nm | 1995 |
| (ix) Edno <i>et al.</i> | | Plasma (human) | Spherisorb ODS (250 \times 4.6 mm, 5 μ m) | 0.04 M disodium hydrogen phosphate (pH 8 by OPA):methanol (60:40 vol/vol) flow rate 1 mL/min | UV 360 nm | 1995 |
| (x) Maya <i>et al.</i> | | Plasma (human) | Lichrospher (250 \times 4 mm, 5 μ m) | Methanol:water:acetic acid | UV 340 nm | 1995 |
| (xi) Amanlou and Dehpour | | Plasma (rat) | μ Bondapak ODS C18 (300 \times 3.9 mm, 10 μ m) | Methanol:phosphate buffer pH 2 (45:55), flow rate 1.5 mL/min | UV 361 nm | 1997 |
| (xii) Yritia <i>et al.</i> | | Plasma (human) | Kromasil C18 (150 \times 4 mm, 5 μ m) | ACN:phosphate buffer 20 mM (pH 3.1) (50:50 vol/vol), flow rate 1 mL/min | UV 360 nm | 1999 |
| (xiii) Dadashzadeh <i>et al.</i> | | Plasma (human) | Novapak C18 (25 cm \times 4.6 mm, 4 μ m) | 0.1 M sodium acetate:ACN:triethylamine (pH 4 by glacial acetic acid) (61:39:0.05 vol/vol), flow rate 1.5 mL/min | UV 330 nm | 2001 |
| (xiv) Ji <i>et al.</i> | | Plasma (human) | Sunfire column (100 \times 2.1 mm, 5 μ m) | Methanol:15 M ammonium formate (pH 3) (60:40 vol/vol) flow rate 0.2 mL/min | ESI-MS | 2005 |
| (xv) Dowling and Malone | | Plasma (bovine) | Agilent Eclipse Plus C18 (50 \times 3 mm, 1.8 μ m) | 0.001 M acetic acid in water:ACN (gradient) | ESI-MS | 2011 |
| (xvi) Calvo <i>et al.</i> | | Plasma and saliva (human) | LichroCART C18 (205 \times 4.6 mm, 5 μ m) | Methanol:2% phosphoric acid (pH 2.7) (70:30 vol/vol), flow rate 1 mL/min | ESI-MS | 2015 |
| 4 | Diclofenac | | | | | |
| (i) Godbillon <i>et al.</i> | | Plasma and urine | Lichrosorb RP 8 (25 cm \times 4 mm, 10 μ m) | Methanol:phosphate buffer (pH 7) (60:40 vol/vol), flow rate 1.3 mL/min | UV 278 nm | 1985 |
| (ii) Sioufi <i>et al.</i> | | Plasma (human) | Novapak C18 (15 cm \times 3.9 mm, 4 μ m) | Methanol:phosphate buffer (pH 7.2) (56:44 vol/vol) flow rate 0.4 mL/min | UV 282 nm | 1991 |
| (iii) Moncrieff | | Serum (human) | Spherisorb ODS (250 \times 4.6 mm) | Methanol:(pH 6.2) sodium phosphate buffer (43:57 vol/vol), flow rate 2 mL/min | FLU Ex = 282 nm Em = 365 nm | 1992 |
| (iv) Blagbrough and Daykin | | Plasma and synovial fluid | Spherisorb ODS (125 \times 4.6 mm, 5 μ m) | Methanol:water (pH 3.3) (63:37 vol/vol), flow rate 1 mL/min | UV 280 nm | 1992 |
| (v) Miller | | Plasma (human) | Nucleosil C18 (15 cm \times 4.6 mm, 10 μ m) | Sodium acetate (pH 7.1):ACN:methanol (52:23:25 vol/vol), flow rate 1.5 mL/min | UV 280 nm | 1993 |

Table 3: Continued

| Sr. no. | Analyte | Matrix (species) | Stationary phase | Mobile phase | Detector | Year |
|---------|-----------------------------|-----------------------------------|--|---|--------------------------|------|
| (vi) | Avgerinos <i>et al.</i> | Plasma and urine (human) | Spherisorb RP C18 (25 cm × 4.5 mm, 5 µm) | ACN:0.1 M sodium acetate (pH 6.3) (35:65 vol/vol), flow rate 1 mL/min | UV 210 nm | 1993 |
| (vii) | Mohamed <i>et al.</i> | Plasma (Beagle dog) | Novapak C18 (150 × 3.9 mm) | ACN:water (pH 3.5 by glacial acetic acid) (50:50 vol/vol), flow rate 1.5 mL/min | UV 278 nm | 1994 |
| (viii) | Mason and Hobbs | Plasma (human) | Nucleosil C18 (25 cm × 4.6 mm, 5 µm) | ACN:water (pH 2.8 by OPA) (35:65 vol/vol), flow rate 1.5 mL/min | UV 280 nm | 1995 |
| (ix) | Li <i>et al.</i> | Plasma (human) | Spherisorb ODS (200 × 4.6 mm, 10 µm) | Methanol:sodium acetate buffer (pH 4.2) (68:32 vol/vol), flow rate 1.4 mL/min | UV 274 nm | 1995 |
| (x) | Kuhlmann <i>et al.</i> | Aqueous humor (human) | Regis SPS 100RP C8 (150 × 4.6 mm, 5 µm) | ACN:30 mM sodium acetate (pH 3 with phosphoric acid) (40:60 vol/vol or 50:50 vol/vol), flow rate 1.3 mL/min | Electrochemical detector | 1997 |
| (xi) | Giagoudakis and Markantonis | Plasma (human) | Spherisorb C18 (25 cm × 4.6 mm, 5 µm) | ACN: 0.1 M sodium acetate (pH 6.3) (35:65 vol/vol), flow rate 1 mL/min | UV 278 nm | 1998 |
| (xii) | Bakkali <i>et al.</i> | Urine (human) | Novapak C18 (15 cm × 3.9 mm, 4 µm) | 10 mM acetate buffer (pH 4):ACN (58:42 vol/vol), flow rate 1 mL/min | UV 210 nm | 1999 |
| (xiii) | Lee <i>et al.</i> | Plasma (human) | Luno phenyl-hexyl column (100 × 2 mm, 3 µm) | ACN:0.02 M potassium phosphate (pH 7) (33:67 vol/vol), flow rate 0.2 mL/min | UV 278 nm | 2000 |
| (xiv) | Arcelloni <i>et al.</i> | Plasma (human) | RP C18 (250 × 4.6 mm, 5 µm) | 25 mM dihydrogen potassium salt (pH 3.5):ACN (30:70 vol/vol), flow rate 1 mL/min | UV 280 nm | 2001 |
| (xv) | Liu and Tsai | Bile (rat) | Microbore RP C18 (150 × 1 mm, 5 µm) | 100 mM sodium dihydrogen phosphate (pH 3.1):ACN (30:70 vol/vol), flow rate 0.05 mL/min | UV 280 nm | 2002 |
| (xvi) | Dorado <i>et al.</i> | Urine (human) | Hypersil ODS (250 × 4.6 mm, 5 µm) | ACN:methanol:THF:water (20:10:3:65 vol/vol/vol/vol), flow rate 0.8 mL/min | UV 282 nm | 2003 |
| (xvii) | Roskar and Kmetec | Synovial fluid (human) | Kromasil C18 (150 × 4.6 mm, 5 µm) | 0.05 M KH ₂ PO ₄ (pH 7 by NaOH):methanol:ACN (58:21:21 vol/vol/vol), flow rate 1 mL/min | UV 205 nm | 2003 |
| (xviii) | Malliou <i>et al.</i> | Urine (human) | Rosil C18 (150 × 4.6 mm, 5 µm) and Lichrosorb RP 18 (250 × 4.6 mm, 5 µm) | Ammonium acetate:methanol:ACN (40:30:30 vol/vol/vol), flow rate 0.6 mL/min | UV 258 nm | 2004 |
| (xix) | Kaphalia <i>et al.</i> | Serum (rat) | RP C18 analytical column (250 × 4.6 mm, 5 µm) | ACN:sodium acetate buffer (pH 5 with acetic acid) (2:1.5 vol/vol) flow rate 0.5 mL/min | UV 280 nm | 2005 |
| (xx) | Sparidans <i>et al.</i> | Plasma (mouse) | Altantis C18 column (100 × 2.1 mm, 3 µm) | Solvent A, 8.5 mM ammonium acetate:0.0075% vol/vol formic acid in water | ESI-QqQ | 2008 |
| (xxi) | Nasir <i>et al.</i> | Plasma and aqueous humor (bovine) | Hypersil C18 (250 × 4.6 mm, 5 µm) | Solvent B, Methanol (gradient) 0.2% Triethylamine:ACN (pH 2.75 by 85% phosphoric acid) (40:60 vol/vol), flow rate 1 mL/min | UV 284 nm | 2011 |
| (xxii) | Aguiar <i>et al.</i> | Plasma (rabbit) | LichroCART RP C18 (125 × 4.6 mm, 5 µm) | 0.7 M acetic acid (pH 2.5 by NaOH):ACN (1:1 vol/vol), flow rate 1 mL/min | DAD 282 nm | 2011 |
| (xxiii) | Emara <i>et al.</i> | Plasma (human) | Symmetry C18 (390 mm ×) | ACN:water (pH 4) (55:45 vol/vol), flow rate 1 mL/min | UV 282 nm | 2012 |
| (i) | Pound and Sears | Plasma (human) | (100) | 0.002% Acetic acid:23% THF in <i>n</i> -hexane (flow rate 1 mL/min) | UV 254 nm | 1975 |
| (ii) | Marunaka <i>et al.</i> | Plasma and urine (rat) | Bondapak C18 (30 cm × 4 mm, 8–10 µm) | Methanol:0.01 M sodium acetate buffer (pH 4) (gradient) | UV 254 nm | 1980 |

Table 3: Continued

| Sr. no. | Analyte | Matrix (species) | Stationary phase | Mobile phase | Detector | Year | |
|-------------|-------------------------------|---|---|---|--|-----------|------|
| A. Steroids | (iii) Hardee <i>et al.</i> | Plasma (horse) | Spherisorb ODS (5 μm) | Methanol:ACN:1% acetate buffer (pH 3.0) (30:20:50 vol/vol/vol), flow rate 1.2 mL/min | UV 254 nm | 1982 | |
| | (iv) Taylor and Westwood | Plasma (equine) | Hypersil C18 (100 × 4.6 mm, 5 μm) | Methanol:0.1 M acetic acid with heptane sulfonic acid (0.01%) (60:40 vol/vol), flow rate 1.5 mL/min | PDA 240 nm | 1995 | |
| | (v) Neto <i>et al.</i> | Plasma and urine (horse) | Lichrospher C18 (125 × 4 mm, 5 μm) | 0.01 M acetic acid:methanol (45:55 vol/vol), flow rate 1 mL/min | UV 254 nm | 1996 | |
| | (vi) Haque and Stewart | Serum | SPS C18 (15 cm × 4.6 mm) | ACN:0.05 M phosphate buffer (pH 7.5) (15:85 vol/vol), flow rate 1 mL/min | UV 265 nm | 1997 | |
| | (vii) Grippa <i>et al.</i> | Serum (equine) | C18 (250 × 4.6 mm, 5 μm) | ACN:water (51:49 vol/vol), containing 0.1% TFA, flow rate 1 mL/min | UV 254 nm | 2000 | |
| | (viii) Asea <i>et al.</i> | Muscle tissue (bovine, equine, and porcine) | C8 (150 × 3.9 mm, 5 μm) | 0.05 M ammonium acetate solution (pH 5):methanol:ACN (53:35:12 vol/vol/vol), flow rate 1 mL/min | UV 270 nm | 2004 | |
| | (ix) Igualada and Moragues | Urine (porcine, bovine, equine, ovine, and coprine) | Zorbax Eclipse C18 (250 × 3 mm, 5 μm) | Formic acid:10 mM (50:50 vol/vol), flow rate 1 mL/min | ESI-MS | 2005 | |
| | 6 | Oxyphenbutazone Sioufi <i>et al.</i> | Plasma (human) | Lichrosorb RP 18 (25 cm × 4.7 mm, 10 μm) | Methanol:phosphate buffer (pH 4) (63:37 vol/vol), flow rate 1.5 mL/min | UV 254 nm | 1983 |
| | 7 | Sulindac (i) Shimek <i>et al.</i> | Plasma (human) | Zorbax ODS (25 cm × 4.6 mm) | Sodium acetate buffer (pH 4 and 5):acetic acid (gradient) | UV 254 nm | 1981 |
| B. Steroids | (ii) Swanson and Boppa | Plasma and urine (human) | Spherisorb ODS column (10 μm) | Methanol:0.4 N sodium acetate buffer (pH 4) (63:37 vol/vol), flow rate 1.2 mL/min | UV 254 nm | 1981 | |
| | (iii) Grgurinovich | Plasma (human) | Waters Phenyl RP column (300 × 3.9 mm, 10 μm) | ACN:GAA:10 mM sodium acetate buffer (pH 4.2) (42:1:57 vol/vol/vol), flow rate 2 mL/min | UV 315 nm | 1987 | |
| | (iv) Ray <i>et al.</i> | Plasma, urine, and feces (human) | Octyl (150 × 4.6 mm, 5 μm) | ACN:acetic acid:water (37.5:1:61.5 vol/vol/vol), flow rate 2 mL/min | UV 329 nm | 1995 | |
| | 8 | Corticosteroids (i) Fluri <i>et al.</i> | Urine (human) | Inertsil 3 ODS (150 × 3 mm, 3 μm) | 1 mM ammonium acetate:ACN (60:40 vol/vol) (gradient) | ESI-Q | 2001 |
| | (ii) Sangiorgi <i>et al.</i> | Urine (bovine) | Symmetry C18 (150 × 4.6 mm, 5 μm) | Water:ACN (gradient), flow rate 1 mL/min | APCI-QqQ | 2003 | |
| | (iii) Rönquist-Nii and Edlund | Tissue of liver and adipose (mouse) | Symmetry C8 (150 × 2.1 mm, 5 μm) | 0.02% TFA in Milli-Q water:0.02% TFA in methanol, flow rate 0.3 mL/min (gradient) | ESI-MS | 2005 | |
| | (iv) Leung <i>et al.</i> | Adipose tissue (human) | Luna C8 (150 × 2 mm, 5 μm) | 0.02% TFA in Milli-Q water:0.02% TFA in ACN (gradient) | ESI-QqQ | 2005 | |
| | (v) Spyridaki <i>et al.</i> | Urine (human) | Supelcosil C8 (3.3 cm × 2.1 mm, 3 μm) | 5 mM acetic acid:ammonium formate (pH 3.8):ACN, flow rate 0.2 mL/min (gradient) | ESI-QqQ | 2005 | |
| | | | Zorbax C8 (150 × 2.1 mm, 5 μm) | 0.1% Acetic acid in water:0.1% acetic acid in ACN (gradient) | ESI-IT | 2006 | |

Table 3: Continued

| Sr. no. | Analyte | Matrix (species) | Stationary phase | Mobile phase | Detector | Year |
|---------|-----------------------------|----------------------------|--|--|-----------------------------------|------|
| (vi) | Ho <i>et al.</i> | Urine (horse) | Supelcosil LC 8 DB (3.3 cm × 2.1 mm, 3 µm) | 5 mM acetic acid:ammonium formate (pH 3.8):methanol (gradient) | ESI-QqQ | 2006 |
| (vii) | Cho <i>et al.</i> | Urine (human) | Hypersil Gold C18 (50 × 2.1 mm, 1.9 µm) | 0.1% Acetic acid in 5% ACN:0.06% acetic acid in 95% ACN (gradient) | ESI-QqQ | 2008 |
| (viii) | Andersen <i>et al.</i> | Urine (porcine and bovine) | Zorbax Eclipse (100 × 2.1 mm, 1.8 µm) and Hypercarb (100 × 2.1 mm, 5 µm) | ACN:0.1% formic acid (3:7) | ESI-MS | 2008 |
| (ix) | Gao <i>et al.</i> | Tissue (mice) | ODS-AQ column (100 × 2 mm, 3 µm) | 0.1% Formic acid in water:0.1% formic acid in methanol | ESI-QqQ | 2009 |
| (x) | Croes <i>et al.</i> | Liver (bovine) | Hypercarb (100 × 2.1 mm, 5 µm) | Water:ACN (20:80), flow rate 300 µL/min | ESI-MS | 2009 |
| (xi) | Dusi <i>et al.</i> | Liver (bovine) | XTerra C18 (150 × 2.1 mm, 3.5 µm) | 0.1% Aqueous acetic acid solution:ACN (gradient) | ESI-QqQ | 2010 |
| (xii) | Deceuninck <i>et al.</i> | Liver (animal) | Acquity BEH C18 (100 × 2.1 mm, 1.7 µm) | 0.5% Acetic acid in water:0.5% acetic acid in ACN, flow rate 0.6 mL/min (gradient) | ESI-MS | 2011 |
| (xiii) | Pavlovic <i>et al.</i> | Urine (bovine) | Restek Ultra II Allure Biphenyl (100 × 2.1 mm, 3 µm) | 0.05% Formic acid in water:0.05% formic acid in methanol (45:55), flow rate 200 µL/min | ESI-Q | 2012 |
| (xiv) | Marcos <i>et al.</i> | Urine (human) | Acquity BEH C18 (100 × 2.1 mm, 1.7 µm) | 0.01% Formic acid in water:methanol with 0.01% formic acid | ESI-QqQ | 2014 |
| (xv) | Rey-Salgueiro <i>et al.</i> | Saliva (pig) | Kinetex C18 (100 × 2.1 mm, 2.6 µm) | Water:methanol:10% HCOOH in water (gradient), flow rate 0.25 mL/min | ESI-QqQ | 2015 |
| 9 | Prednisolone | | | | | |
| (i) | Loo <i>et al.</i> | Plasma (human) | Lichrosorb (250 × 3.2 mm, 5 µm) | 0.2% GAA:6% methanol:30% methylene chloride in <i>n</i> -hexane (vol/vol), flow rate 120 mL/h | UV 254 nm | 1977 |
| (ii) | Frey and Frey | Urine (Human) | (250 × 3.2 mm, 5 µm) | Hexane:diethylether:ethanol:THF:GAA (59.9:31.2:3.6:5.0:3 vol/vol), flow rate 1.8 mL/min | UV 254 nm | 1982 |
| (iii) | Ui <i>et al.</i> | Serum (human) | Zorbax-SIL (25 cm × 4.6 mm, 5 µm) | Dichloromethane:methanol (92.5:7.5 vol/vol), flow rate 1 mL/min | UV 254 nm | 1982 |
| (iv) | Prasad <i>et al.</i> | Plasma (swine) | Lichrosorb Si-60 (25 cm × 4.6 mm) | Methylene chloride:water:saturated methylene chloride:THF:methanol:glacial acetic acid (664.5:300:10:25:0.5), flow rate 0.8 mL/min | UV 254 nm | 1986 |
| (v) | Carlin <i>et al.</i> | Plasma (swine) | Zorbax C18 (25 × 0.46 cm, 5–6 µm) | THF:water (25:75 vol/vol), flow rate 1 mL/min | UV 240–242 nm | 1988 |
| (vi) | Yamaguchi <i>et al.</i> | Plasma (human) | TSK-gel ODS (250 × 4.6 mm, 5 µm) | Methanol:ACN:1 M ammonium acetate (38:25:45 vol/vol), flow rate 1 mL/min | FLU Ex = 350 nm Em = 390 nm | 1991 |
| (vii) | Musson <i>et al.</i> | Aqueous humor (rabbit) | Chemcosorb 5 ODS (150 × 4 mm, 5 µm) | Isopropanol:water with 2 mL of H ₃ PO ₄ , pH 3 adjusted by 1 M NaOH (250:750 vol/vol) | UV 245 nm | 1991 |
| (viii) | Garg and Jusko | Urine (human) | Zorbax C18 (250 × 4.6 mm, 5–6 µm) | Methylene chloride:glacial acetic acid:methanol (91.3:7.5:1.2 vol/vol), flow rate 2 mL/min | UV 254 nm | 1991 |
| (ix) | Jusko <i>et al.</i> | Plasma (human) | Zorbax SIL (250 × 4.6 mm, 5–6 µm) | Methylene chloride:heptane:glacial acetic acid:ethanol (600:350:10:35 vol/vol/vol/vol) | UV 254 nm | 1994 |
| (x) | Hirata <i>et al.</i> | Serum (human) | Hypersil ODS (25 × 0.46 cm) | Solvent A, Isopropanol:0.05 M acetate buffer pH 4.5 (10:90 vol/vol) | UV 254 nm | 1994 |
| | | | | Solvent B, Isopropanol:0.05 M acetate buffer pH 4.5 (gradient) | | |

Table 3: Continued

| Table 3: Continued | | | | | | |
|----------------------------------|-----------------------------------|---|--|---|-----------------------------------|------|
| Sr. no. | Analyte | Matrix (species) | Stationary phase | Mobile phase | Detector | Year |
| (xi) Döppenschmitt <i>et al.</i> | Serum (human) | Lichrosorb (250 × 4 mm, 5 µm) | ThermoHypersil (250 × 4.6 mm, 5 µm) | <i>n</i> -hexane:dichloromethane:methanol:acetic acid (266:120:26:0.8 vol/vol/vol/vol), flow rate 2 mL/min | UV 242 nm | 1995 |
| (xii) AbuRuz <i>et al.</i> | Plasma and urine (human) | | | Dichloromethane:water saturated DCM:methanol:THF:GAA (66.45:30.2:5.1% vol/vol/vol/vol), flow rate 2 mL/min | UV 240 nm | 2003 |
| (xiii) Frerichs and Tornatore | Serum (human) | Symmetry C18 (30 × 2.1 mm, 3.5 µm) | Symmetry C18 (30 × 2.1 mm, 3.5 µm) | Methanol:5 mM acetate buffer pH 3.25 (gradient), flow rate 400 µL/min | ESI-MS | 2004 |
| (xiv) DiFrancesco <i>et al.</i> | Plasma (human) | | | 5 mM ammonium acetate pH 3.5:methanol (gradient), flow rate 400 µL/min | ESI-QqQ | 2007 |
| (xv) Ding <i>et al.</i> | Adipose tissue (human) | Luna C18 (50 × 2 mm, 5 µm) | Genesis C18 (50 × 4.6 mm, 3 µm) | 0.02% Formic acid in water:0.02% formic acid in methanol (gradient), flow rate 0.35 mL/min | ESI-QqQ | 2009 |
| (xvi) Chen <i>et al.</i> | Plasma (human) | | | 0.1% Formic acid in water:0.1% formic acid in ACN (gradient), flow rate 1 mL/min | ESI-QqQ | 2009 |
| (xvii) Ionita <i>et al.</i> | Plasma (human) | Zorbax-SB Phenyl (100 × 2.1 mm, 1.8 µm) | Acquity UPLC BEH C18 (50 × 2.1 mm, 1.7 µm) | ACN:water:formic acid (32:68:0.1 vol/vol/vol), flow rate 0.140 mL/min | ESI-MS | 2009 |
| (xviii) Mewhinney <i>et al.</i> | Plasma, urine, and saliva (human) | | | Solvent A, 2 mmol/L ammonium acetate in water with 0.1% formic acid | ESI-MS | 2010 |
| (xix) Fung <i>et al.</i> | Plasma (human) | Zorbax C18 (50 × 2.1 mm, 3.5 µm) | Acquity UPLC BEH C18 (50 × 2.1 mm, 1.7 µm) | Solvent B, 2 mmol/L ammonium acetate in methanol with 0.1% formic acid, flow rate 0.4 mL/min | QTOF | 2011 |
| | | | | Solvent A, 10 mM ammonium formate:0.1% formic acid in water | | |
| (xx) Li <i>et al.</i> | Milk (bovine) | | Restek Ultra (100 × 2.1 mm, 3 µm) | Solvent B, 10 mM ammonium formate:0.1% formic acid in 80% methanol:20% ACN (gradient), flow rate 0.3 mL/min | ESI-QqQ | 2012 |
| (xxi) Pavlovic <i>et al.</i> | Urine (bovine) | | | 0.1% Formic acid in water:0.1% formic acid in ACN (gradient), flow rate 0.3 mL/min | Q-MS | 2012 |
| (xxii) Liu <i>et al.</i> | Milk (cow) | | BEH C18 (100 × 2.1 mm, 1.7 µm) | 0.05% Formic acid in water:0.05% formic acid (45:55 vol/vol), flow rate 200 µL/min | ESI-QqQ | 2016 |
| (xxiii) Huang <i>et al.</i> | Serum and urine (rat) | | | Solvent A, 0.1% formic acid in water | ESI-MS | 2016 |
| | | | | Solvent B, 0.1% formic acid in ACN, flow rate 0.3 mL/min | | |
| 10 | Triamcinolone | | | 0.1% Formic acid in water:0.1% formic acid in ACN (gradient) | | |
| (i) Döppenschmitt <i>et al.</i> | Plasma (human) | Lichrospher RP 18 (250 × 4 mm, 5 µm) | Lichrospher RP 18 (125 × 4.6 mm, 5 µm) | Methanol:water:THF (vol/vol/vol), flow rate 1 mL/min | UV 252 nm | 1996 |
| (ii) Głowka <i>et al.</i> | Plasma (human) | | | ACN:0.3 mM OPA (pH 4.6) (470:530 vol/vol), flow rate 2 mL/min | FLU Ex = 360 nm Em = 460 nm | 2006 |
| (iii) Vieira <i>et al.</i> | Plasma (rat) | Kromasil C18 (250 × 4.6 mm, 5 µm) | | Methanol:water (72:28 vol/vol), flow rate 0.8 mL/min | UV 254 nm | 2010 |
| C. Microtubule inhibitor | | | | | | |
| 11 | Colchicine | | | | | |
| (i) Jiang <i>et al.</i> | Plasma (human) | Zorbax C18 (150 × 4.6 mm, 5 µm) | | Formic acid:10 mM ammonium acetate:methanol (1:49:75 vol/vol/vol) | ESI-MS | 2007 |

Table 3: Continued

| Sr. no. | Analyte | Matrix (species) | Stationary phase | Mobile phase | Detector | Year |
|---------|-----------------------------------|--|--|---|-----------|------|
| 12 | (ii) Chen <i>et al.</i> | Plasma (mouse) | Diamonsil C18 (250 × 4.6 mm, 5 µm) | ACN:phosphoric acid solution (27:73 vol/vol), flow rate 1 mL/min | UV 350 nm | 2007 |
| | (iii) Bourgogne <i>et al.</i> | Plasma (human) | Hypersil C18 (50 × 2 mm, 3 µm) | 0.1% Formic acid in water:0.1% formic acid in methanol (gradient) | ESI-QqQ | 2013 |
| | (iv) Kovvasu <i>et al.</i> | Plasma (human) | Synergy (75 × 4.6 mm, 4 µm) | 10 mM ammonium formate (pH 3.5):methanol (20:80 vol/vol) | ESI-QqQ | 2018 |
| | II. Chronic gout | | | | | |
| 13 | A. Uricosuric drug | | | | | |
| | 12 Sulfipyrazone | | | | | |
| | (i) Inaba <i>et al.</i> | Serum (dog) | Micro-Pak (25 cm × 2.2 mm, 10 µm) | Dioxane:methanol (65:35 vol/vol), flow rate 0.7 mL/min | UV 254 nm | 1975 |
| | (ii) Wong <i>et al.</i> | Plasma and urine (Male albino Wistar rat and rabbit) | Lichrosorb (250 × 2.8 mm, 10 µm) | 0.1 M ammonium acetate in ACN:water (pH 5 adjusted with acetic acid) 30:70 or 35:75 vol/vol, flow rate 0.5 mL/min | UV 275 nm | 1978 |
| | (iii) Bjornsson <i>et al.</i> | Plasma and urine (human) | µBondapak C18 (30 cm × 0.39 mm, 10 µm) | 0.1 M ammonium acetate in ACN:water (30:70 vol/vol), flow rate 1 mL/min | UV 270 nm | 1980 |
| | (iv) Jakobsen and Pedersen | Plasma (human) | Spherisorb ODS (250 × 4.6 mm, 5 µm) | Methanol:0.02 M phosphate buffer pH 7 (40:60 vol/vol) | UV 254 nm | 1981 |
| | (v) Godbillon <i>et al.</i> | Plasma (human) | Lichrosorb RP 8 (25 cm × 4.6 mm, 10 µm) | 2.2 mM OPA:ACN:ethanol (50:35:15 vol/vol/vol), flow rate 3 mL/min | UV 254 nm | 1982 |
| | (vi) de Vries <i>et al.</i> | Plasma and urine (human) | µBondapak C18 (300 × 3.9 mm, 10 µm) | Solvent A, 0.1 M ammonium acetate:ACN (780:220 vol/vol) | UV 254 nm | 1983 |
| | (vii) Tam <i>et al.</i> | Plasma (human) | Radial Pak C18 (11.5 cm × 8 mm, 5 µm) | Solvent B, ACN (gradient) | UV 254 nm | 1984 |
| | Benzbromarone | | | ACN:0.02 M phosphate buffer pH 7.0, flow rate 2 mL/min | UV 254 nm | |
| 14 | (i) Vergin and Bishop | Serum (human) | µBondapak C18, (30 cm × 4 mm, 10 µm) | Methanol:water:ACN:ethyl acetate:acetic acid (72:23:3:1:1) | UV 254 nm | 1980 |
| | (ii) Arnold <i>et al.</i> | Plasma and urine (human) | Nucleosil C8 (125 × 4.6 mm, 5 µm) | ACN:5 mM sodium dihydrogen phosphate (pH 3.5 adjusted with phosphoric acid) (60:40 vol/vol), flow rate 0.5 mL/min | UV 280 nm | 1991 |
| | (iii) Wu <i>et al.</i> | Plasma, urine, feces, and bile (rat) | RP C18 (75 × 4.6 mm, 3.5 µm) | 0.2% Formic acid in ACN:0.2% formic acid in water (gradient) | UV 235 nm | 2012 |
| | B. Uric acid synthesis inhibitors | | | | | |
| | Febuxostat | | | | | |
| | (i) Wang <i>et al.</i> | Plasma (human) | Capcell Pak C18 (100 × 4.6 mm, 5 µm) | ACN:5 mM ammonium acetate:formic acid (85:15:0.015), flow rate 0.6 mL/min | ESI-QqQ | 2012 |
| | (ii) Vaka <i>et al.</i> | Plasma (human) | Zorbax SB-C18 (75 × 4.6 mm, 3.5 µm) | ACN:5 mM ammonium formate (60:40 vol/vol), flow rate 0.5 mL/min | ESI-QqQ | 2013 |
| | (iii) Chandu <i>et al.</i> | Plasma (human) | Ascentis Express C18 (50 × 4.6 mm, 3.5 µm) | 10 mM ammonium formate:ACN (20:80 vol/vol), flow rate 0.8 mL/min | ESI-QqQ | 2013 |
| | | | | | | |
| | | | | | | |

Table 3: Continued

| Sr. no. | Analyte | Matrix (species) | Stationary phase | Mobile phase | Detector | Year |
|-----------------------------|-------------|------------------|--|---|-----------|------|
| (iv) Xie <i>et al.</i> | | Plasma (human) | XTerra MS C8 (150 × 2.1 mm, 5 µm) | 0.1% Formic acid in ACN:0.1% formic acid in water (gradient) | ESI-MS | 2014 |
| (v) Choudhury <i>et al.</i> | | Plasma (human) | Zorbax SB-CN (50 × 4.6 mm, 3.5 µm) | 0.2% Formic acid solution in water:methanol (10:90 vol/vol), flow rate 0.5 mL/min | ESI-QqQ | 2014 |
| (vi) Wu <i>et al.</i> | | Plasma (human) | Zorbax SB C18 (50 × 4.6 mm, 5 µm) | 0.2% Formic acid in water:ACN (gradient) | ESI-QqQ | 2015 |
| 15 | Allopurinol | | | | | |
| (i) Reinders <i>et al.</i> | | Serum (human) | Lichrospher100 RP18 (250 × 4 mm, 5 µm) | 0.02 M sodium acetate with acetic acid 30%, pH 4.5, flow rate 1 mL/min | UV 254 nm | 2007 |
| (ii) Kasawar <i>et al.</i> | | Plasma (human) | Symmetry Shield RP18 (150 × 3.9 mm, 5 µm) | 0.01% Formic acid in water and ACN (95:5 vol/vol) | ESI-MS | 2011 |
| (iii) Liu <i>et al.</i> | | Plasma and urine | Agilent Eclipse C18 (150 × 4.6 mm, 3.5 µm) | Solvent A, 5 mM ammonium formate:0.1% formic acid (95:5 vol/vol) Solvent B, methanol:5 mM ammonium formate (95:5 vol/vol) | ESI-MS | 2013 |
| (iv) Rathod <i>et al.</i> | | Plasma (human) | Hypersil Gold (150 × 4.6 mm, 5 µm) | 0.1% formic acid in water:ACN (98:2 vol/vol) flow rate 0.5 mL/min | ESI-MS | 2016 |

APCI-MS = atmospheric pressure chemical ionization-mass spectrometry, DCM = Dichloromethane, TFA = Trifluoroacetic acid, GAA = Glacial acetic acid, OPA = Ortho phosphoric acid, ESI-IT = Electrospray ionization- ion trap, QqQ = Triple Quadrupole, FLU = Fluorescence, THF = Tetrahydrofuran




Figure 3: Categories of antigout drugs on which impurity profiling, forced degradation, and bioanalytical study are studied




Figure 4: Different matrices used for impurity and forced degradation profiling of antigout drugs




Figure 5: Different species used for bioanalytical method of antigout drugs




Figure 6: Different matrices used for bioanalytical method of antigout drugs

Archive of SID




Figure 7: Different columns used for of impurity profiling, forced degradation, and bioanalytical method of antigout drugs




Figure 8: Types of elution performed in analysis for impurity, forced degradation profiling, and bioanalysis of antigout drugs

method for determination of NAP in the presence of its impurities. Study revealed total seven impurities, which are characterized on the basis of stress degradation studies. No considerable degradation was observed in photolytic degradation.

Marwa *et al.*^[22] developed HPLC-DAD for separation and analysis of NAP and esomeprazole in the presence of their chiral impurities and enantiomeric purity determination in tablets. This method separates the four isomers of the two drugs simultaneously. The chiral impurities (R-isomers of NAP and omeprazole) detected at 1% level.

Indomethacin: Kwong *et al.*^[23] reported HPLC method for efficient separation of indomethacin (IDM) and its impurities. Study revealed total four impurities. This method was found to be sensitive, linear, and showed good repeatability.

Novakova *et al.*^[24] reported simple, sensitive, and validated method for determination and quantitation of IDM and its degradant product by RP-HPLC using UV as detector. Faster separation was obtained with analytical column Zorbax SB CN (Agilent technologies, Prague, Czech Republic) as compared




Figure 9: Different detectors used for impurity profile, forced degradation, and bioanalytical method of antigout drugs, Fluorescence, Electron capture detector

to Zorbax phenyl analytical column for the separation of IDM and its two degradation products, 4-chloro-benzoic acid and 5-methoxy-2-methylindoleacetic acid.

Temussi *et al.*^[25] developed method for the determination of photostability and photodegradation products of IDM in aqueous media. The drug was photochemically degraded affording eight photoproducts. All photoproducts were isolated by preparative HPLC and characterized by nuclear magnetic resonance (NMR) techniques (correlation spectroscopy [COSY], heteronuclear single quantum coherence spectroscopy [HSQC], heteronuclear multiple bond coherence [HMBC], and nuclear Overhauser effect spectroscopy [NOESY]) and liquid chromatography–mass spectrometry (LC–MS) experiments.

Haq *et al.*^[26] developed an environmentally benign approach for rapid analysis of IDM using stability indicating RP-HPLC method. The stability study of IDM was carried out, which revealed six degradant products, of which two were acid hydrolysis, one was base hydrolysis, two were oxidative hydrolysis, and one was thermal hydrolysis product.

Piroxicam: Bartsch *et al.*^[27] developed three methods of stability indicating assays for the determination of piroxicam. First method was HPLC, whereas second was High performance thin layer chromatography and third is capillary electrophoresis (CE) method. The aim of the study was mainly selective determination of piroxicam, no separation of all degradation products was necessary. The relative standard deviation (RSD) for the three methods at each concentration gave the best results for quantitation using HPLC.

Diclofenac: Hajkova *et al.*^[28] developed reverse-phase chromatographic method with UV spectrometric detection for the simultaneous determination of methylparaben, propylparaben, and sodium diclofenac and its degradation product in a topical emulgel. Degradation product of diclofenac was 1-(2,6-dichlorophenyl)-indolin-2-one occurring in a formulation after long-term stability tests.

Galmier *et al.*^[29] developed the LC–MS method on degradation products of diclofenac in aqueous dosage form in accelerated storage conditions. Electrospray ionization – mass spectrometry

Archive of SID

(ESI-MS) spectra were used to study diclofenac fragmentation and to characterize the structures of degradation products. The study revealed the presence of three degradation products.

Sulindac: Krier *et al.*^[30] developed HPLC method for quantification of sulindac and its related impurities. This method was optimized using design of experiment methodology and the diclofenac sodium (DS) concept. The impurity study of sulindac was carried out, which revealed its three related impurities.

Steroids

Corticosteroids: Hymer^[31] developed simple, accurate, and reproducible HPLC method for the determination of three known major impurities present in corticosteroids (CRS). This method used gradient elution method by using UV detector.

Lu *et al.*^[32] reported a sensitive rugged and robust HPLC method, which was suitable for the identification assay of betamethasone sodium phosphate and betamethasone acetate, and for the identification and estimation of their impurities/degradants. This method could separate a total of B2 potential impurities and degradation products from the two APIs and also from each other.

Prednisolone: Marley *et al.*^[33] developed RP-HPLC method for the determination of prednisolone acetate (PA) and impurities in an ophthalmic suspension. This method was simple, accurate, precise, and specific, which was carried out according to the ICH guidelines, and all eight known impurities were separated.

Triamcinolone: Matysová *et al.*^[34] developed a novel RP-HPLC method for the determination of active component triamcinolone (TMC) acetate, its degradation product TMC, occurring in formulation after long-term stability tests. The main impurity TMC was found in cream formulation.

Chronic gout

Uric acid inhibitor

Febuxostat: Kadivar *et al.*^[35] studied impurity profile of febuxostat API and carryover impurity from the intermediate stage and raw materials using LC-MS quadrupole time-of-flight instrument and were characterized after they were synthesized by infrared and NMR. Four impurities were identified as amide, sec-butyl, des-cyano, and des-acid in febuxostat drug analog.

Bioanalytical Method

Acute gout

Nonsteroidal anti-inflammatory drug

Naproxen: Loenhout *et al.*^[36] developed HPLC method for the quantitative analysis of NAP and its major metabolite des-methyl-NAP in biological fluid samples (plasma and urine). Two methods of detection were compared, that is, UV spectrophotometry and spectrophotofluorometry. The

sensitivity of the fluorimetric detection was higher than that of the UV detection.

Wanwimolruk^[37] reported a simple, rapid, and sensitive method for the determination of NAP in human plasma. The sensitivity of the method was improved with the help of microbore column. This method is suitable for its use in clinical studies.

Karidas *et al.*^[38] developed extractionless HPLC method for the determination of NAP in human plasma and urine with UV detection at 278 nm. The method was sufficiently sensitive for biopharmaceutical studies, after the oral administration of a single sustained release dose.

Mikami *et al.*^[39] developed HPLC method for the simultaneous determination of NAP, nabumetone, and its major metabolite 6-methoxy-2-naphthylacetic acid. The procedure described is rapid, simple, selective, and suitable for routine analysis of pharmaceuticals and PK studies in human urine samples.

Elsinghorst *et al.*^[40] developed a sensitive, precise, and accurate quantitative liquid chromatography tandem mass spectrometry (LC-MS/MS) method for the measurement of NAP in human plasma and completely validated according to the current Food and Drug Administration (FDA) and European Medicines Agency (EMA) guidelines. The maximum concentration (C_{max}) value was found to be 8.61%.

Patel *et al.*^[41] developed UPLC-MS/MS method for the simultaneous determination of sumatriptan (SUM) and NAP in human plasma of 28 healthy subjects. This method was validated as per the US FDA guidelines. The C_{max} , time taken to achieve maximum concentration (T_{max}), and half-life ($t_{1/2}$) values for SUM and NAP were 78.04 ± 6.50 and 60.36 ± 3.12 µg/mL, 0.88 ± 0.14 and 3.98 ± 0.35 h, and 2.24 ± 0.22 and 14.07 ± 0.83 h, respectively.

Ahmadi and Bapirzadeh^[42] reported a simple, rapid, partial selective and sensitive HPLC method for the analysis of NAP. This method used in-tube SPME-liquid liquid liquid extraction, an ideal sample preparation technique, because of fast operation and low expense. This method is a useful tool for the screening and determination of acidic drugs in clinical control and forensic analysis.

Shi *et al.*^[43] developed a novel LC-MS method to simultaneously determine the concentration of naproxen and its active metabolite in rat plasma. The C_{max} , T_{max} , and $t_{1/2}$ values for naproxen and NAP were 23.4 ± 7.1 and 3610 ± 1620 ng/mL, 8 ± 1.8 and 8 ± 2.1 h, 11.7 ± 3.2 and 5.5 ± 1.8 h, respectively.

Indomethacin: Terweij-Groen *et al.*^[44] developed a HPLC method for the quantitative analysis of IDM and salicylic acid in blood serum and urine. The recovery was found to be 88% and 77% for IDM and salicylic acid, respectively. The results of this study do not solve the clinical issue of a possible interaction of IDM and salicylic acid.

Bernstein and Evans^[45] developed a rapid and sensitive HPLC-fluorescence method for the quantitative analysis of IDM and

Archive of SID

its metabolite in urine. This is used in laboratory for the analysis of I and II metabolites in biological fluids.

Shimek *et al.*^[46] developed a rapid, specific method for the quantitation of tolmetin, IDM, and sulindac and their respective metabolites in plasma. The method described here can be recommended for routine patient monitoring or for PK studies.

Greizerstein and McLaughlin^[47] developed the method to determine the concentration of IDM in blood of rats by HPLC–UV method. The simple extraction and the short time required for analyses of blood samples make this method very economical and fast for the analyses of samples.

Smith and Benet^[48] developed an HPLC method for the determination of IDM and its two primary metabolites in urine. Inter- and intraday precisions were smaller than 10% for IDM, desmethyl (DMI), and deschlorobenzoyl (DBI). This method has been used successfully for bioavailability studies.

De Zeeuw *et al.*^[49] developed a highly sensitive HPLC method combined with post-column alkaline hydrolysis of IDM. The utility of this method in measuring IDM concentrations in small sample volumes was collected from microperfusion of an isolated segment of renal proximal tubule. The lower limit of detection was reported to be approximately 0.02 µg/mL for IDM.

Sauvaire *et al.*^[50] developed a liquid chromatographic method for determination of IDM and its prodrug apyramide in plasma. In this method, experimental design approach was used. A PK study in dogs and rats provided information about the biological disposition of the ester prodrug.

Stubbs *et al.*^[51] developed an improved method for the determination of IDM in plasma and urine by RP-HPLC. The results were in good agreement with their target values and showed relative standard deviation of 3.6% and 2.7% for plasma and 3.9% and 3.1% for urine for low and high values, respectively. It has been successfully used to assay many clinical samples and has been proved to be very rugged.

Brown *et al.*^[52] developed an HPLC method for the determination of IDM serum concentrations. Recovery ranged from 0.1 to 4 µg/mL. Their approach was to adjust each IDM concentrations and clinical response until PDA closure was achieved.

Kim *et al.*^[53] developed quantification of IDM in serum by HPLC using fluorescence detection. This method could be used for PK and bioavailability studies of IDM in man, and tissue distribution in small laboratory animals. The highest recovery (102%) was obtained with a buffer of pH 6.6.

Avgerinos and Malamataris^[54] developed a similar simple, rapid, and sensitive method for the determination of IDM in both human plasma and urine. The %RSD < 4 indicated that the method was sufficiently precise. The method is currently being used for a PK and bioequivalence investigation of controlled release formulations.

Hubert *et al.*^[55] developed a fully automated RP-HPLC method for the determination of IDM in plasma. The absolute recovery of the drug is 70%. The method is also applicable to the bioavailability studies of IDM not only after oral administration but also after external application to the skin as a spray solution.

Mawatari *et al.*^[56] developed an HPLC method involving post-column photochemical reaction and fluorimetric detection for the determination of IDM in serum. The mean recovery was found 94.3%. This method is sensitive and specific enough to estimate IDM in human serum and is expected to be useful in therapeutic drug monitoring.

Singh *et al.*^[57] developed a simple and reproducible HPLC and gas chromatography–mass spectrometry (GC–MS) method for the simultaneous analysis of several acidic drugs in horse plasma and urine. The recovery of each drug from plasma was calculated as 95%, and the assay showed good precision. The capillary GC–MS column provided better separation of the drugs than the reversed phase C18 HPLC column. This study indicated that the sensitivities of different acidic drugs were comparable when determined by the GC–MS method.

Caturla and Cusido^[58] developed a sensitive, specific, and selective HPLC method for the determination of IDM, suxibuzone, phenylbutazone, and oxyphenbutazone in plasma. The recovery of suxibuzone, phenylbutazone, and oxyphenbutazone was 92.8%–99.0%, 90.8%–99.5%, and 96.4%–101.5%, respectively. SPE method is less time-consuming and prevents degradation of the compounds than the LLE. It is useful for PK studies, drug monitoring, or doping control of these substances in plasma.

Kubo *et al.*^[59] developed a sensitive and specific fluorimetric method for the determination of IDM in serum by HPLC using in-line oxidation with hydrogen peroxide. The recovery of IDM was found to be 95%. This method can be used for routine therapeutic monitoring and also for the determination of other compounds that are oxidized with hydrogen peroxide.

Vree *et al.*^[60] developed an HPLC method for the determination of IDM, its metabolites, and their glucuronides in human plasma and urine. The C_{max} , T_{max} , and $t_{1/2}$ values for IDM were 5.4 µg/mL, 1.0 h, and 0.84 h, respectively. In urine, the parent drug (IDM) as well as the metabolite and conjugate (DMI and DBI) were present. The possible metabolite DBI was not detected in urine. In this method, the effect of probenecid was studied, which inhibits the formation of both the ether and the acyl glucuronide of DMI.

Niopas and Mamzoridi^[61] developed a simple, rapid, relatively inexpensive, precise, accurate, and sensitive HPLC method for the determination of IDM and mefenamic acid in plasma. The accuracy was found to be nearly 100% for both drugs. This method is useful for routine clinical monitoring of IDM and mefenamic acid in small volumes of plasma and particularly use for pediatric use.

Sato *et al.*^[62] developed a simple, rapid, and sensitive method for the determination of IDM in plasma by HPLC with UV

Archive of SID

detection. The recoveries of the drug were found to be nearly 100%. This method is very suitable for the therapeutic drug monitoring of IDM in premature infants with symptomatic PDA and also in patients undergoing conventional IDM therapy.

Liu *et al.*^[63] developed a rapid, accurate, and sensitive automated analytical method for the determination of IDM in animal plasma using an on-line column switching HPLC technique. The accuracy of IDM ranged from -0.62% to 3.22%. The method has been successfully used to provide PK data in a large number of diverse pharmaceutical studies.

Dawidowicz *et al.*^[64] developed a simple and sensitive method of free IDM analysis in plasma samples using HPLC-UV detection. The method is characterized by high yield (recovery approximately 97%) and detection limit (3 ng/mL), which is so far one of the lowest values reported for HPLC method.

Michail and Moneeb^[65] designed an HPLC-DAD assay, combining SPE with pre-column derivatization to determine methotrexate (MTX) and IDM in human urine. The stability was tested under the conditions recommended by the FDA, which are freeze and thaw stability, short-term temperature stability, long-term stability, processed samples stability, and stock solution stability. They were hoped that further studies concerning the urinary levels of MTX and NSAID in cancer.

Liu *et al.*^[66] developed a LC-MS/MS for measuring plasma and uterine tissue levels of IDM in rabbits treated with IDM-mediated Copper Intrauterine devices (Cu-IUDs). The mean recoveries of IDM at low, medium, and high concentration levels were $90.8\% \pm 4.6\%$, $88.5\% \pm 4.4\%$, and $89.0\% \pm 9.1\%$. This method was successfully applied to investigate the absorption and uterine distribution of IDM in rabbits after insertion of IDM-mediated Cu-IUDs.

Wang *et al.*^[67] developed LC-ESI-MS for quantitative determination of IDM in maternal plasma and urine of pregnant patients. The relative standard deviation of this method was less than 8%, and the accuracy found was between the range 90% and 108%. This method is suitable for determining the PK parameters of IDM during pregnancy.

Piroxicam: Twomey *et al.*^[68] reported an HPLC method for the analysis of piroxicam in plasma. The recovery of piroxicam was 73.6%. This method was reproducible and accurate and did not require chemical modification of drug.

Dixon *et al.*^[69] developed a rapid, sensitive, and reproducible method for the quantitative analysis of tenoxicam and piroxicam in plasma. Mean recovery of piroxicam and tenoxicam was found to be $81 \pm 3.0\%$ and $81 \pm 7.9\%$, respectively. The mean plasma half-life of piroxicam was 46.7 h.

Richardson and Ross^[70] developed an HPLC method for the analysis of piroxicam and its metabolite 5-hydroxy-piroxicam in human plasma and urine. Recoveries of piroxicam and 5-hydroxy-piroxicam ranged between approximately 80% and

90%. The method was routinely used in laboratories for the analysis of human plasma and urine in clinical studies.

Macek and Vacha^[71] developed a rapid, sensitive, and selective method for the determination of piroxicam in human plasma by HPLC. The %RSD was 2.9% and was sufficient for PK studies.

Boudinot and Ibrahim^[72] reported a precise, specific, and sensitive HPLC method for the assay of piroxicam in human plasma. The mean recovery of piroxicam was found to be $91\% \pm 6\%$.

Milligan^[73] developed an HPLC method for the determination of piroxicam and its major metabolites in plasma, urine, and bile. The %RSD of piroxicam and 5-hydroxy-piroxicam in plasma, urine, and bile was found to be $<2.9\%$ and $<8.0\%$, $<4.9\%$ and $<4.5\%$, and $<3.9\%$, respectively.

Cerretani *et al.*^[74] developed a rapid, precise, and sensitive HPLC method for the determination of piroxicam in rat plasma, muscle, and skin. The C_{max} , T_{max} , and $t_{1/2}$ (distribution) and $t_{1/2}$ (elimination) values for piroxicam in plasma, muscle, and skin were 58.3, 23.2, and 257.4 $\mu\text{g/mL}$; 4, 1, and 2 h; 11.6, 0.4, and 1.2 h; and 10.9, 185, and 29.5 h. The method was adopted for a PK study in rats.

Avgerinos *et al.*^[75] reported a simple, rapid, and sensitive extractionless HPLC method for the simultaneous determination of piroxicam and 5-hydroxy-piroxicam in human plasma. The %RSD was found to be $<4.6\%$ and the detection limit was 0.05 $\mu\text{g/mL}$. It is useful in the determination of PK parameter for drug formulation studies.

Edno *et al.*^[76] developed a reproducible, rapid, and sensitive HPLC assay method for the quantitation of piroxicam in plasma. The mean recovery was found to be $95 \pm 3\%$. The method was validated according to good laboratory practices guidelines and was applied to check the compliance of treatment for patient with rheumatological disorders.

Maya *et al.*^[77] developed a rapid and sensitive method for the determination of piroxicam in plasma. The mean relative recovery was found between the range 94% and $108\% \pm 3.67\%$. This method is also used in bioavailability study.

Amanlou and Dehpour^[78] developed a simple, sensitive, and rapid HPLC method to measure plasma concentration of piroxicam in rat. The mean extraction recovery for piroxicam was found to be $82\% \pm 6\%$.

Yritia *et al.*^[79] described a fully automated method for the determination of piroxicam in human plasma using an on-line SPE, and this was compared with the same chromatographic method using off-line SPE. The validation of the method showed good recoveries (over 90%). Two methods are suitable to quantify drug level in PK studies, but the online method saves a lot of time and needs less manipulation.

Dadashzadeh *et al.*^[80] reported a simple, reliable, accurate, and precise HPLC method for the determination of piroxicam in

Archive of SID

plasma. A mean recovery of $100.09\% \pm 6.52\%$ was observed in the concentration range of 0.1–3 $\mu\text{g/mL}$. This method is also used in the bioavailability study.

Ji *et al.*^[81] developed a rapid, sensitive, and reliable LC–MS/MS method for the determination of piroxicam, meloxicam, and tenoxicam in human plasma. The C_{max} and T_{max} values of piroxicam were $6.1 \pm 1.4 \text{ ng/mL}$ and 33 h, respectively. This method was successfully applied to a PK study of piroxicam after application of transdermal piroxicam patches to humans.

Dowling and Malone^[82] developed a fast, simple, sensitive, and selective LC–MS/MS method for the determination of firocoxib, propyphenazone, romifenazone, and piroxicam in bovine plasma. Accuracy of the methods in plasma was between 93% and 102%.

Calvo *et al.*^[83] developed a rapid, sensitive, and selective LC–MS/MS method for the simultaneous determination of piroxicam and 5'-hydroxy-piroxicam in saliva and human plasma. The C_{max} , T_{max} , and $t_{1/2}$ values for piroxicam and 5'-hydroxy-piroxicam in plasma and saliva were 2275.9 ± 367.7 and $133 \pm 47.2 \text{ ng/mL}$; 50.9 ± 24.8 and $5.9 \pm 2-8 \text{ ng/mL}$; 4.0 ± 1.2 and $53.6 \pm 14.7 \text{ h}$; 4.7 ± 2.4 and $54.9 \pm 14.2 \text{ h}$; 50.7 ± 8.8 and $4167.6 \pm 1318.2 \text{ h}$, respectively. The stabilities in plasma were evaluated at different conditions including short-term stability, post-processing stability, freezing, and thawing.

Diclofenac: Godbillon *et al.*^[84] developed a sensitive and selective HPLC method for the determination of diclofenac and its monohydroxy-related metabolites in plasma and urine. The mean recovery of DS, 4'-OH, and 5'-OH was found in the range of 97%–109%, 93%–97%, and 100%–101%. The dihydroxy-related metabolite could not be assayed because of interference.

Sioufi *et al.*^[85] determined diclofenac in plasma using a fully automated analytical system combining liquid–solid extraction with liquid chromatography. The overall accuracy was ranging from 95% to 101% and the %RSD was 1.0%–9.3%. The automated determination of drugs in biological fluids increases the sample throughput.

Moncrieff^[86] developed an RP-HPLC method with fluorimetric detection of DS in serum. The relative recovery was 98.2%–102%. This method is sufficiently sensitive to follow the PK of all dosing routes for diclofenac other than topical application.

Blagbrough and Daykin^[87] reported an HPLC assay method to determine the levels of NAP, ibuprofen, and diclofenac in plasma and synovial fluid. The mean recovery from plasma extracts ranged within 89.5%–95.1% at a concentration between 100 and 1000 ng/mL . This method was used in clinical studies of the three drugs in a patient with osteoarthritis and rheumatoid arthritis.

Miller^[88] developed an HPLC method to determine diclofenac in human plasma using automated column switching. The C_{max} , T_{max} , and $t_{1/2}$ values were found to be 1400 ng/mL , 2.6 h, and 0.9 h, respectively. The mean absolute recovery was 90.5%.

Avgerinos *et al.*^[89] developed an extractionless HPLC method for the determination of diclofenac in human plasma and urine. The %RSD was found to be <4 in plasma and <5 in urine. The method was also applicable in hospitalized patients.

Mohamed *et al.*^[90] developed an improved HPLC method for the quantitation of diclofenac in dog plasma. The C_{max} and T_{max} values were found to be $78.2 \pm 12.5 \text{ } \mu\text{g/mL}$ and $0.4 \pm 0.19 \text{ h}$, respectively, and the mean recovery was $98\% \pm 5.5\%$. The method was applied for the determination of the PK parameters of diclofenac given by oral and intravenous (IV) bolus administration to dogs.

Mason and Hobbs^[91] reported a simple, rapid HPLC method for the determination of diclofenac in human plasma. The recovery was found to be 82%–97%. This method could be used for clinical research.

Li *et al.*^[92] developed an RP-LC method for the determination of DS in human plasma. The mean percentage recoveries of DS were $91.3\% \pm 10.1\%$ and $93.2\% \pm 3.9\%$ for the low (0.20 $\mu\text{g/mL}$) and high (1.20 $\mu\text{g/mL}$) concentrations, respectively. This method was successfully applied in clinical trials.

Kuhlmann *et al.*^[93] developed an RP-HPLC method for the simultaneous bioanalysis of diclofenac and oxybuprocaine in human aqueous humor. The detection limits were 0.5 ng/mL for diclofenac and 50 ng/mL for oxybuprocaine. This method has improved sensitivity and selectivity that enable kinetic studies at very low concentration.

Giagoudakis and Markantonis^[94] reported an HPLC method to determine the diclofenac and flurbiprofen in plasma. The average accuracy was 98.8% for diclofenac. The assay was applied in an ongoing PK and PD study of NSAIDs.

Bakkali *et al.*^[95] developed an HPLC method for the analysis of DS, IDM, and phenylbutazone in human urine. Absolute recoveries were approximately 50% for phenylbutazone and 85% for DS and IDM.

Lee *et al.*^[96] reported an automated narrow bore HPLC method using column switching for the simultaneous determination of aceclofenac and diclofenac from human plasma. The C_{max} , T_{max} , and $t_{1/2}$ values for aceclofenac and diclofenac were 6.6 ± 1.1 and $3.0 \pm 0.7 \text{ } \mu\text{g/mL}$; 1.5 and $1.3 \pm 0.4 \text{ h}$; and 2.3 ± 0.04 and $2.1 \pm 0.1 \text{ h}$, respectively.

Arcelloni *et al.*^[97] developed an HPLC method to quantify the diclofenac in human. The significant differences between treatments were evaluated by Student's *t*-test. The results were obtained after rectal administration; T_{max} was $1.0 \pm 0.5 \text{ h}$ with a C_{max} of $1650 \pm 600 \text{ ng/mL}$, which was significantly higher than after the slow release oral one where C_{max} was $630 \pm 390 \text{ ng/mL}$ and T_{max} was $6.0 \pm 2.0 \text{ h}$. The method was statistically significant at $P < 0.05$.

Liu and Tsai^[98] described a rapid and sensitive method for the determination of diclofenac in rat bile using *in vivo* microdialysis by HPLC. The C_{max} and $t_{1/2}$ values of diclofenac without cyclosporine A and with cyclosporine A were found

Archive of SID

to be 798 ± 110 and 1187 ± 146 ng/mL and 31 ± 4 and 35 ± 4 min, respectively. The C_{\max} increased by adding cyclosporine A. This method has good clinical evidence, showing the value of diclofenac for the treatment of biliary colic.

Dorado *et al.*^[99] developed an HPLC method to measure simultaneously diclofenac and its metabolites in human urine. The mean accuracy was greater than 99% for diclofenac and 98%, 99%, and 97% for 3'-OH, 4'-OH, and 5'-OH metabolites, respectively, over 4–12 mg/L range.

Roskar and Kmetec^[100] reported an HPLC method to determine diclofenac in the synovial fluid. The recovery of diclofenac was above 87% with a mean value of 91%, and the standard deviation (SD) was less than 5.0%. This method is reliable and suitable for monitoring diclofenac levels after oral or cutaneous administration of the drug to patient with inflammatory and degenerative joint diseases.

Malliou *et al.*^[101] developed a sensitive and efficient method for the simultaneous determination of clobutinol, diclofenac, meloxicam, and nimesulide in urine. The intra- and inter-day accuracy and precision at low, medium, and high concentrations were in the range 1.76%–5.06% of %RSD. This method can be applicable for PK study.

Kaphalia *et al.*^[102] developed a simple and rapid method to determine diclofenac and its major 4'-hydroxy metabolite in serum. Recovery for the 4'-hydroxy metabolite in serum was found to consistently average from 0.10% to 12%, whereas recovery of diclofenac in serum declined from 0.45% to 0.37%. This method is suitable for the measurement of a major diclofenac metabolite in experimental studies.

Sparidans *et al.*^[103] reported a validated LC–MS/MS assay for quantitative analysis of diclofenac and three primary metabolites (i.e., DF–G, 4'-H–DF, and 5'-H–DF) in plasma. The accuracies were found in the range of 90%–108%, within day precisions were <10%, and between day precisions were <13%. The assay will be valuable tool in mouse PK studies. For studies in men, partial revalidation will be required.

Nasir *et al.*^[104] developed HPLC–UV method for the simultaneous determination of timolol maleate, rosuvastatin calcium, and DS in pharmaceuticals and physiological fluids. The recoveries in human plasma were 98.72%, 96.04%, and 95.14% for timolol maleate, rosuvastatin, and DS, respectively, whereas in aqueous humor, they were 94.99% and 98.23% for timolol maleate and DS, respectively. This method can also be applied for routine laboratory practice.

Aguiar *et al.*^[105] reported an HPLC method for the determination of DS in rabbit plasma and the characterization of its crystalline forms (i.e., anhydrous and hydrate) on the antipyretic effect. The C_{\max} and T_{\max} values for DS were found to be 2.998 µg/mL and 1.529 h, respectively. The results showed that hydrate and anhydrous forms of DS have a similar PK and PD profile at least in reducing fever in rabbits.

Emara *et al.*^[106] developed a bioanalytical HPLC method for monitoring DS in human plasma. The C_{\max} and T_{\max} values in modified release products (Retard and sustained release) were 765.21 and 722.12 ng/mL and 6.0 and 3.0 h, respectively. This method was validated according to the US FDA guidelines.

Phenylbutazone: Pound and Sears^[107] reported a rapid, sensitive, and precise method for the simultaneous determination of phenylbutazone and oxyphenbutazone in plasma by high-speed liquid chromatography. The mean recovery values of $99.44\% \pm 1.17\%$ and $99.28\% \pm 1.26\%$ were obtained for phenylbutazone and oxyphenbutazone, respectively. It can be used for the analysis of phenylbutazone and oxyphenbutazone in multiple dose as well as single dose PK studies.

Marunaka *et al.*^[108] reported a precise and sensitive HPLC method for the determination of phenylbutazone and its metabolites in plasma and urine. The detection limit for phenylbutazone, oxyphenbutazone, and for γ -hydroxyphenylbutazone was 0.05 µg/mL. The overall recoveries of phenylbutazone, oxyphenbutazone, and γ -hydroxyphenylbutazone were $96.7\% \pm 1.7\%$, $93.1\% \pm 3.7\%$, and $81.7\% \pm 4.2\%$, respectively. The present assay method was then applied to the plasma and urine of other animals and men to which phenylbutazone and its metabolites were added.

Hardee *et al.*^[109] developed an HPLC method for the simultaneous determination of flunixin, phenylbutazone, oxyphenbutazone, and γ -hydroxyphenylbutazone in equine plasma. Absolute recoveries found were $99\% \pm 2\%$ for oxyphenbutazone, $96\% \pm 3\%$ for NAP, $97\% \pm 4\%$ for flunixin, $96\% \pm 3\%$ for phenylbutazone, and $98\% \pm 2\%$ for the γ -OH. This study also presented results for clinical cases of intestinal ischemia treated with non-steroidal anti-inflammatories.

Taylor and Westwood^[110] developed an HPLC method for the quantitation of phenylbutazone and oxyphenbutazone in equine plasma. Confirmatory analysis was achieved by GC–MS with on-column derivatization (methylation) of back extracted residues from the HPLC method. The accuracy ranges found were 53.5%–63.1% for phenylbutazone (PB) and 43.3%–47.2% for oxyphenbutazone (OPB).

Neto *et al.*^[111] described a method for the qualitative and quantitative determination of phenylbutazone and oxyphenbutazone in horse urine and plasma samples by HPLC and GC–MS method. The limit of detection was 0.5 µg/mL and the limit of quantitation was 1.0 µg/mL for both drugs. The recoveries were found to be 83% and 105% for PB and OPB, respectively. This method gives enough sensitivity to be used in the anti-doping control of racehorses.

Haque and Stewart^[112] reported a direct injection method for the determination of phenylbutazone and its active metabolite oxyphenbutazone in serum by using the semipermeable surface (SPS) column. Recoveries of phenylbutazone and oxyphenbutazone on the SPS column were determined to be

Archive of SID

79.7% \pm 2.7% and 94.2% \pm 4.5%, respectively. This method is useful for PK and TK studies of both analytes.

Grippa *et al.*^[113] described an RP-HPLC method for the simultaneous analysis of selected steroidal and NSAIDs in equine serum suitable for anti-doping control. The overall recoveries were found to be 89.0% \pm 7.8% for hydrocortisone, 88.2% \pm 0.4% for dexamethasone, 37.9% \pm 0.9% for oxyphenbutazone, 6.5% \pm 0.9% for probenecid, 78.1% \pm 5.5% for IDM, and 51.5% \pm 2.7% for phenylbutazone.

Asea *et al.*^[114] developed a sensitive liquid chromatographic method for the analysis of phenylbutazone drug residues in bovine, equine, and porcine muscle tissues. The mean recovery of phenylbutazone from bovine muscle tissues was found to be 58%.

Igualada and Moragues^[115] developed an ion-trap LC–MS method to determine oxyphenbutazone and phenylbutazone residues in the urine of several animal species. The method was validated according to the requirements of the 2002/657/EC European decision, and the calculated decision limit (CC α) and detection capability (CC β) were 2 and 3 ng/mL, respectively.

Oxyphenbutazone: Sioufi *et al.*^[116] described a simple and rapid HPLC method for the determination of oxyphenbutazone in human plasma. The mean recovery was found 98.4% \pm 7.1%. It is useful to determine OPB in small volumes of plasma when the drug is administered to children.

Sulindac: Shimek *et al.*^[46] described a rapid, specific HPLC method for the determination of IDM, sulindac, and tolmetin by isocratic and gradient elution to determine these drugs and metabolites. The recoveries were found to be 66.41% \pm 0.71% for IDM, 69.04% \pm 1.13% for sulindac, and 73.06% \pm 2.65% for tolmetin. This method can be recommended for routine patient monitoring or PK studies.

Swanson and Boppana^[117] developed sensitive HPLC method for the measurement of sulindac and its metabolites in human plasma and urine. The recovery was found to be 89% for sulindac from both plasma and urine. This method can be applied to studies on the bioavailability, metabolism, and clearance of sulindac in human.

Grgurinovich^[118] reported a sensitive HPLC of sulindac and its sulfone and sulfide metabolites in plasma. The recovery was found to be 95.1% \pm 5.24% for sulindac. This method does not require solvent programming to achieve suitable separation and elution times.

Ray *et al.*^[119] developed an HPLC method for the determination of (Sulindac sulfone) derivative of sulindac-1 in human plasma, urine, and feces. The extraction efficiency of FGN-1 was approximately 75% from plasma, 90% from urine, and 97% from feces.

Steroids

Corticosteroids: Fluri *et al.*^[120] reported the development of a method for the confirmation of synthetic CRS in doping urine

samples by LC-ESI-MS. Detection limits were determined as \leq 1 ng/mL, the limit of confirmation was at 1–5 ng/mL. This method is selective and sensitive, which assures the exclusion of false positive results obtained by corticosteroid group enzyme-linked immunosorbent assay screening tests.

Sangiorgi *et al.*^[121] described an LC–MS method for the determination of CRS in bovine urine. The recoveries were found at two different levels (i.e., 5 μ g/kg % relative coefficient of variation (RCV) and 1 μ g/kg % RCV), 55.6% (11.2%) and 45.8% (12.4%) for TMC, 68.7% (10.1%) and 97.0% (8.8%) for prednisone (PN), 72.8% (9.6%) and 103.7% (9.5%) for PN, 87.5% (9.1%) and 106.4% (8.1%) for dexamethasone, 91.4% (8.2%) and 113.2% (4.2%) for betamethasone, 70.7% (9.0%) and 87.6% (9.5%) for flumethasone, 71.9% (5.6%) and 95.5% (7.2%) for TMC acetone, respectively. Neutral loss mode is suitable for the detection of all the CRS for their simultaneous determination with a limit of detection of 1 μ g/kg. The method fully meets the European Union (EU) legislation requirement for the determination of the banned drugs.

Rönquist-Nii and Edlund^[122] developed an LC–MS/MS method for the determination of corticosterone and 11-dehydrocortisone (11-DHC) levels in mouse liver and adipose tissue and hydrocortisone and cortisone levels in human adipose tissue. The absolute recoveries from spiked mouse liver homogenate were 96% for corticosterone and 100% for 11-DHC. The recoveries from spiked mouse adipose homogenate were 99% for corticosterone and 93% for 11-DHC. The recoveries from human adipose tissue homogenate were 100%, 92%, and 89% for hydrocortisone and 95%, 88%, and 86% for cortisone.

Leung *et al.*^[123] described LC–MS/MS methods for the screening of CRS and basic drugs in horse urine. For CRS, the precision ranged from 2% to 11%, and the relative retention times ranged from 0% to 0.49%. For basic drugs, the precision ranged from 5% to 17%, and the relative retention times ranged from 0.65% to 1.83%. This method is useful for the screening of CRS and basic drugs in equine sports at low ppb (parts per billion) levels in horse urine.

Spyridaki *et al.*^[124] developed an LC-ESI-MS ion trap method for the determination of CRS and the quantification of ephedrine, salbutamol, and morphine in urine. The recovery was found to be from 74% to 113%, and 100% recovery was observed only for prednisolone (PO). This method is useful in Olympic Games Athens for doping control analysis.

Ho *et al.*^[125] reported an LC–MS method for the screening of anabolic steroids, CRS, and acidic drugs in horse urine. The recoveries found for anabolic steroids ranged from 31% to 81%, and for CRS, they ranged from 4% to 87%, and for acidic drugs, they ranged from 7% to 97%. The purpose of the study is for doping control in equine sports.

Cho *et al.*^[126] developed a method to measure the levels of the 21 endogenous CRS in urine samples obtained from the patients with prostate cancer and Benign prostatic hyperplasia

Archive of SID

by LC–MS/MS. The recoveries were found in the range of 85%–106%, with the limit of quantitation in the range from 0.5 to 2 ng/mL and accuracy (%bias) of the assay at 95.1%–105.4%. This method has a sufficient sensitivity to allow the profiling of both gluco- and mineralo-CRS at a time.

Andersen *et al.*^[127] developed a method for the quantitative determination of CRS in urine by LC–MS. This method was validated according to EU regulations. The relative and absolute recoveries were found to be 96%–103% and 81%–89%, respectively.

Gao *et al.*^[128] developed a novel SPE-LC-MS/MS method for the quantitative determination of six CRS in *ex vivo* samples. The linearity range was 0.4–30,000 fmol. This method is developed to assess the effect of pharmacological inhibitors of 11B-Hydroxysteroid dehydrogenase-1.

Croes *et al.*^[129] developed an LC/Tandem mass spectrometry method for the determination of 12 CRS in bovine liver, which has been optimized and validated in accordance with the European Commission decision 2002/657 EC. The mean recoveries were between 91% and 109%, repeatability and reproducibility coefficients of maximum were 13.7% and 18.0%, respectively.

Dusi *et al.*^[130] developed an LC–MS/MS method for the simultaneous determination of nine corticosteroid residues in bovine liver samples. The recoveries were above 62% for all analytes. Repeatability and reproducibility for all analytes were below 7.65% and 15.5%, respectively. This method applied to the confirmation of corticosteroid treatments within Italian National Residue Control Program.

Deceuninck *et al.*^[131] developed an ultra-high performance liquid chromatography (UHPLC) method for the determination of maximum residual limit (MRL)–regulated CRS in liver from various species. This method was validated according to the 2002/657/EC requirements. The decision limit (CC α) values were 2.31, 2.35, 11.93, and 11.88 μ g/kg, whereas the detection capability (CC β) values were 2.57, 2.63, 13.60, and 14.02 μ g/kg for dexamethasone, betamethasone, PO, and methylprednisolone, respectively. The method was developed in order to obtain an efficient separation of stereoisomers.

Pavlovic *et al.*^[132] developed a quantitative LC–ESI single quadrupole MS method for the determination of cortisol (CRL), cortisone, PO, and PN in bovine urine. RSDs were found to be 4.9% for PN, 6.8% for cortisone, 10.5% for CRL, and 15.6% for PO. This method might be used in the screening of glucocorticoid abuse.

Marcos *et al.*^[133] developed an LC–MS method for accurate and precise measurement of endogenous corticosteroid profiles in human urine. Recoveries were higher than 80% and intra-assay precisions were below 20% at three concentration levels. In this article, they studied 47 steroids in healthy individuals. This method is useful for clinical purposes due to satisfactory

quantitative results, short analysis time, low sample volume, and simple sample preparation.

Rey-Salgueiro *et al.*^[134] developed an LC-MS method for the simultaneous determination of five CRS in pig saliva. The analyte recoveries were in the range of 60 to 90%. There was a significant correlation detected between CRL and CRS, and they hypothesized that CRL and CRS could be used both as biomarkers of non-stress in the saliva of pigs.

Prednisolone: Loo *et al.*^[135] described a sensitive, specific HPLC method for the determination of PO in human plasma. The mean recovery was found to be 98.6%. This method is also useful for assessing the specificity and accuracy of a radioimmunological assay for PO.

Frey and Frey^[136] developed an HPLC method for the simultaneous measurement of PN, PO, and 6 β -hydroxyprednisolone in human urine. The analytical recovery for 6 β -hydroxyprednisolone and for [³H] prednisolone was 70% \pm 2% and 85% \pm 3%, respectively.

Ui *et al.*^[137] described a reliable and rapid method for the determination of PN and PO in human serum by HPLC. The recovery was observed 83.4% for each of the steroids. This method has good applicability, which shows that conversion of PN into PO is impaired in patients with liver cirrhosis.

Prasad *et al.*^[138] described an HPLC method for the simultaneous determination of PA, PO, PN, cortisone, and hydrocortisone in swine plasma. The average recovery of PA, PO, and PN at 20 ng/mL was between 70% and 90%.

Carlin *et al.*^[139] developed an RP-HPLC method for the analysis of PA and related corticoids in swine plasma. The recoveries were found to be 87% \pm 13%.

Yamaguchi *et al.*^[140] developed an LC method for the determination of PO and PN in plasma. The recoveries of PO and PN were 86.4% \pm 3.3% and 88.3% \pm 3.5%, respectively. This method may be useful for the determination of TMC and methylprednisolone in biological materials.

Musson *et al.*^[141] developed an RP-HPLC assay method for PO, PA, and prednisolone sodium phosphate in rabbit aqueous humor and ocular physiological solution. The coefficient variation was found in between 3.99% and 9.11% for pred-P, pred-A, and PO.

Garg and Jusko^[142] developed an HPLC method for the simultaneous determination of PN, PO, and their major hydroxylated metabolites in human urine. The extraction recovery of PO was approximately 75%, whereas for the other steroids, including PN, the recoveries averaged to approximately 65%. This method is also useful for routine clinical studies.

Jusko *et al.*^[143] developed a precise, reproducible, and specific HPLC assay method for the simultaneous determination of PN, CRL, and PO in human plasma. The mean recoveries were found in the range from 72% to 78%.

Archive of SID

Hirata *et al.*^[144] developed an HPLC method for the simultaneous determination of deflazacort metabolites II and III, CRL, cortisone, PO, and PN in human serum. The recoveries were found in the range between 82.7% and 102.7%.

Döppenschmitt *et al.*^[145] developed an HPLC method for the simultaneous determination of PO, PA, and hydrocortisone in human serum. The absolute recoveries were found for three analytes in the range between $72.6\% \pm 2.1\%$ and $89\% \pm 4.3\%$. This method is useful to estimate the side effect of the exogenous glucocorticoids on the serum levels of the physiological glucocorticoid hydrocortisone.

AbuRuz *et al.*^[146] developed a simple, rapid HPLC method for the simultaneous determination of PO and CRL in plasma and urine. The recovery of CRL from plasma range between 87.0% and 93.1%, and from urine, it was between 85.4% and 101.3%. The recovery of PO from plasma ranged between 82.2% and 89.8%, and from urine, it was between 82.0% and 102.2%.

Frerichs and Tornatore^[147] developed an LC–MS/MS method for the determination of the glucocorticoids, PN, PO, dexamethasone, and CRL in human serum. The relative standard deviation was between 2.41% and 7.11% for the between and within day measurements. This method is useful to support clinical pharmacology studies of these glucocorticoids in post-renal transplant patients of varying health status.

Difrancesco *et al.*^[148] developed an LC–MS/MS method for the simultaneous analysis of several glucocorticoids, mycophenolic acid (MPA), and MPA glucuronide in human plasma. The %RSD for intraday and inter-day variation was between 0.76% and 9.57% for all analytes. This assay provides a clinical tool for therapeutic drug monitoring.

Ding *et al.*^[149] developed an LC–MS/MS method for the determination of PO to the estimation of 11β -hydroxysteroid dehydrogenase activity in human adipose tissue. The percentage recovery of PO was found ranged between 96.6% and 103%.

Chen *et al.*^[150] developed an accurate, sensitive, and robust LC–MS/MS method for the simultaneous quantitation of PO and dipyridamole in human plasma. The mean extraction recoveries were in the range of 92.2%–104%. This method is applicable to a PK study and provide efficient and timely support for further clinical studies.

Ionita *et al.*^[151] developed a highly sensitive, selective, and robust LC–MS/MS method for the simultaneous quantification of CRL, cortisone, PO, and PN in human plasma. Recovery was found to be within 98%–105% for each of the four compounds. This method is successfully used to analyze over 500 incurred samples obtained from kidney transplant recipients who were treated with PN as well as with up to 21 other medications.

McWhinney *et al.*^[152] described an UHPLC–MS/MS method for a routine laboratory to determine CRL, cortisone, PO, dexamethasone, and 11 -deoxycortisol in plasma, plasma ultrafiltrate, urine, and saliva. The average recovery was found

to be 108%. This method should be suitable for use in a high-volume routine laboratory.

Fung *et al.*^[153] reported an LC–high resolution mass spectrometry method for quantifying PN and PO in human plasma. The extraction recovery was 68%–69% for both analytes. The assay accuracy was in between 98.4% and 106.3%.

Li *et al.*^[154] developed an UPLC–MS/MS method for the simultaneous quantification of amoxicillin (AMOX) and PO in bovine milk. The mean recoveries were 89.2%–92.3% for AMOX and 98.7%–102.8% for PO. The method is validated according to European Commission requirements.

Pavlovic *et al.*^[132] developed an LC–ESI method for the determination of CRL, cortisone, PO, and PN in bovine urine. Intraday and intermediate precision were estimated where $RSD < 17\%$. This method is considered as a possible biomarker of illegal treatment.

Liu *et al.*^[155] developed a reliable UPLC–MS/MS method for the simultaneous measurement of AMOX, clavunic acid (CLAV), and Prednisolone (PSL) in cow's milk. The recoveries of three analytes were found within 84.2% to 101.45%. This method is applicable to study the comparative kinetic behavior of AMOX, CLAV, and PSL after intermammary infusing in healthy mastitis cows.

Huang *et al.*^[156] developed a metabonomic method based on UPLC–MS to profile the metabolic alternations of PO-induced osteoporosis. The %RSD for urine and serum were found in between 3.6%–9.0% and 1.1%–5.2%, respectively. The work also showed that the metabonomic method is a promising tool in the research of traditional Chinese compound medicine.

Triamcinolone: Döppenschmitt *et al.*^[157] developed an HPLC method for the simultaneous determination of TMC acetonide and hydrocortisone in human plasma. The absolute recoveries of two analytes were found in the range $89.5\% \pm 4.5\%$ to $100.1\% \pm 2.3\%$.

Główka *et al.*^[158] described a sensitive and specific RP-HPLC method for the determination of small quantities of TMC in plasma in the presence of endogenous steroids. The recovery of TMC ranged from 76% to 83%. This method is useful for PK and bioavailability studies of TMC, administered in small doses.

Vieira *et al.*^[159] reported a specific and reliable HPLC method for the simultaneous quantitative determination of TMC acetonide and budesonide in microdialysate and rat plasma. The mean absolute recovery at low, medium, and high quality control samples was 109%, 103%, and 99.6%. This method is applicable for the bioanalysis of TMC in clinical studies using free drug monitoring via microdialysis.

Microtubule inhibitor

Colchicine: Jiang *et al.*^[160] developed a rapid and sensitive method to determine colchicine in human plasma by LC–MS/

Archive of SID

MS. The mean recoveries of colchicine were found to be 95.6%–105.3%. This method was applied to a PK study of colchicine in healthy volunteers given an oral dose of 2.0 mg.

Chen *et al.*^[161] described a simple and sensitive HPLC method for the determination of colchicine in mouse plasma. The mean recoveries of colchicine from mouse plasma at the concentration of 3, 120, and 900 ng/mL were 92.8%, 94.6%, and 96.0%. This method is used in the study of PK of colchicine after IV injection and intraperitoneal injection.

Bourgogne *et al.*^[162] developed an automated LC–MS/MS method for the determination of colchicine in human plasma using Turbulent flow chromatography-LC-MS/MS. The accuracy was found to be 84.4%–110%. This method is suitable for monitoring intoxication in patients undergoing chronic treatment and is routinely applied to toxicological samples.

Kovvasu *et al.*^[163] described a simple, reliable, and rapid LC–MS/MS method for the determination of colchicine in human plasma. The mean recovery was found to be $97.3\% \pm 1.30\%$. This method was fully validated as per the US FDA guidelines, and well suitable for PK or bioavailability/bioequivalence application.

Chronic gout

Uricosuric drugs

Sulfinpyrazone: Inaba *et al.*^[164] described HPLC method for determination of sulfinpyrazone (SO) in serum. The percentage recovery was found to be 80%–94%. This method is specific enough and useful when a patient is on multiple medications.

Wong *et al.*^[165] described a simple, rapid RP-HPLC method for micro-determination of SO in biological fluids. The average recovery of SO was $78.52\% \pm 4.04\%$. This method is also allowed for the direct analysis of urine samples containing a sufficiently high concentration of the drug.

Bjornsson *et al.*^[166] described a simple, specific, sensitive, and accurate HPLC assay for the simultaneous analysis of SO and two of its metabolites in plasma and urine. The total recoveries by two different extraction procedures were found to be between the range of 50%–65% and 70%–80%.

Jakobsen and Pedersen^[167] described HPLC method for the simultaneous determination of SO and four of its metabolites. The percentage recovery of SO and its metabolites (SO₂, S, SOOH, and SOH) was 85% and 85%, 88%, 16% and 99%, respectively.

Godbillon *et al.*^[168] described an HPLC method for the analysis of the sulfide metabolite of SO in plasma. The mean recovery was found to be 95%–102%. This method is useful for the assay of sulfide in plasma.

de Vries *et al.*^[169] developed an HPLC method for the analysis of SO and its metabolites in human plasma and urine. The recoveries were found to be 90%–100%. The method is useful

in human PK studies, in the drug level monitoring of patients, and in animal experimentation.

Tam *et al.*^[170] described a simple and rapid HPLC method for the analysis of SO and four of its metabolites in human plasma. The recovery was found to be higher than 99%. The applicability of this method was shown by measuring SO and its metabolites in human plasma after different routes of administration.

Benzbromarone: Vergin and Bishop^[171] described a specific, sensitive, and rapid procedure for the simultaneous determination of benzbromarone and benzarone in serum concentration using HPLC method. The recovery was found to be $80\% \pm 1.45\%$ for benzbromarone over a range of 1.29–10.30 µg/mL. This method is also suitable for measuring or determining urine levels and plays a subordinate role in benzbromarone therapy.

Arnold *et al.*^[172] developed an LC–MS method using a thermospray interface where seven benzbromarone metabolites in human plasma and urine were identified. In this work, they used electron impact ionization for off-line technique and thermospray for on-line interfacing; by comparing these techniques, they concluded that EI is suitable for identification of major metabolites, which requires relatively large amounts of analytes.

Wu *et al.*^[173] developed an HPLC–quadrupole time of flight-MS method for the investigation of benzbromarone metabolites in rat plasma, urine, feces, and bile samples. Among the 17 metabolites, the deoxidized phase-I metabolites and an array of phase-II metabolites–surface conjugates were detected in the biological samples.

Uric acid synthesis inhibitors

Febuxostat: Wang *et al.*^[174] developed an LC–MS/MS method for the determination of febuxostat in human plasma. The mean recovery of febuxostat and internal standard (IS) was found to be 96.16% and 98.6%, respectively. The intra- and inter-day precision were less than 7.9% and 7.2%, respectively. Instability of analyte in human plasma was not observed when stored at –20°C for 31 days.

Vaka *et al.*^[175] reported a sensitive LC–MS/MS method for the quantification of febuxostat in human plasma. The mean recovery of febuxostat and IS was found to be $82.7\% \pm 3.64\%$ and $88.5\% \pm 0.75\%$, respectively. The C_{\max} in plasma was 5.21 ± 0.80 µg/mL attained at 0.91 ± 0.27 h (T_{\max}). The area under curve (AUC)_{0–t} and AUC from zero to infinity were 15.1 ± 3.56 and 15.1 ± 3.57 µg·h/mL, respectively. The $t_{1/2}$ was found to be 4.23 ± 0.69 h.

Chandu *et al.*^[176] developed an LC–MS/MS method for quantification of febuxostat in human plasma. The overall average recovery of febuxostat and Febuxostat D7 (i.e., IS) was found to be 81.59% and 89.28%, respectively. The C_{\max} value for test and reference product of febuxostat was found to be 3065.46 and 3726.09 ng·h/mL, and T_{\max} was 1 h for both. The

Archive of SID

test and the reference product had similar $t_{1/2}$ (approximately 6.5 h). The analysis of variance study showed that period, sequence, and treatment had no significant effect on C_{\max} , T_{\max} , AUC_{0-t} , and AUC from zero to infinity.

Xie *et al.*^[177] developed an HPLC–MS/MS method for the simultaneous determination of active metabolite of febuxostat (67M-1, 67M-2, and 67M-4) in human plasma. The recovery was greater than 90.13% for all analytes in plasma sample. The method was statistically significant because of no difference in $t_{1/2}$ ($P > 0.05$, paired sample t -test) and T_{\max} (Wilcoxon signed-rank test) between two dosing groups.

Choudhury *et al.*^[178] developed and validated a simple, novel, and sensitive assay method for the estimation of febuxostat in human plasma using HPLC–MS/MS. The mean recovery was found to be $93.16\% \pm 2.873\%$, whereas recovery of IS was reported to be $91.60\% \pm 3.815\%$. The AUC_{0-t} and C_{\max} value for febuxostat were found to be $31.401 \pm 5.949 \mu\text{g}\cdot\text{h/mL}$ and $4.936 \pm 0.440 \mu\text{g/mL}$ at the time $2 \pm 0.426 \text{ h}$ (T_{\max}). The method will be widely applicable in preclinical PK, regulatory TK, clinical kinetic study, and bioequivalence study.

Wu *et al.*^[179] described an LC–MS/MS method for the simultaneous determination of febuxostat and its three active metabolites in human plasma. The extraction recoveries of the analyte from human plasma ranged from 87.1% to 98.6% with maximum RSD of 13.7% and IS recovery of $89.4\% \pm 3.8\%$.

Allopurinol: Reinders *et al.*^[180] developed and validated a simple quantitative assay using RP-HPLC method for allopurinol and oxypurinol in human serum. Intra- and inter-day precision showed coefficient of variation $< 15\%$ over the complete concentration range; accuracy was within 5% for allopurinol and oxypurinol. This method was proven to be valid for samples of patients with gout who were frequently using concomitant medications.

Kasawar *et al.*^[181] reported a rapid and highly sensitive LC–MS/MS method for the determination of allopurinol and oxypurinol in human plasma. The CV for assay precision was found to be $< 6.94\%$, and the accuracy was found to be $> 96.03\%$.

Liu *et al.*^[182] developed a sensitive and reliable LC–MS/MS method to determine the concentration of allopurinol and its active metabolite oxypurinol in human plasma and urine. The extraction recoveries of allopurinol from plasma and urine were 51.1%, 55.8%, and 53.0%; and 79.3%, 80.1%, and 83.8%, respectively. The extraction recoveries of oxypurinol from plasma and urine were 72.4%, 75.6%, and 76.7%; and 75.0%, 75.4%, and 78.0%, respectively. This method is useful for preclinical experiment and clinical trials.

Rathod *et al.*^[183] described a simple, reliable, and reproducible LC–MS/MS method for the simultaneous determination of allopurinol and its active metabolite oxypurinol in human plasma for a PK/bioequivalence study. The accuracy for analytes varied from 94.74% to 97.03% and from 94.10% to 98.88%, respectively, for both analytes. The method was

successfully applied for a clinical study involving healthy subjects.

Conclusion

This systematic review was able to gather all records present in the scientific literature about validated impurity profile, force degradation, and bioanalytical methods for the quantitation of antigout agent. This review provides information of earlier research work on antigout agent with a view to help the analyst to know about which research work was carried out.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

- Toomula N, Kumar A, Kumar SD, Bheemidi VS. Development and validation of analytical method for pharmaceuticals. *J Anal Bioanal Tech* 2011;2:127.
- Analytical method development and validation. Particle Sciences. Technical Brief 2009;5.
- ICH. Impurities in new drug substances Q3A (R2). International Conference on Harmonization. Geneva, Switzerland: IFPMA; 2006.
- ICH. Impurities in new drug products Q3B (R2). International Conference on Harmonization. Geneva, Switzerland: IFPMA; 2006.
- ICH. Impurities: Guideline for residual solvents Q3C (R6). International Conference on Harmonization. Geneva, Switzerland: IFPMA; 2016.
- Ahuja S, Alsante KM. Handbook of Isolation and Characterization of Impurities in Pharmaceuticals Separation Science and Technology. Elsevier Publisher Academic Press Vol. 5. 1-7, June 2003.
- ICH. Guideline for elemental impurities Q3D. International Conference on Harmonization. Geneva, Switzerland: IFPMA; 2014.
- ICH. Stability testing of new drug substances and products Q1A (R2). International Conference on Harmonization. Geneva, Switzerland: IFPMA; 2003.
- ICH. Specifications: Test procedure and acceptance criteria for new drug substances and new drug products: Chemical substances Q6A. International Conference on Harmonization. Geneva, Switzerland: IFPMA; 2005.
- Salunkhe MN, Gite SD, Kachave RN. Recent trends in impurity profiling and forced degradation of antihypertensive drugs. *J Liq Chromatogr Relat Technol* 2017;40:813-31.
- ICH. Stability testing: Photostability testing of new drug substances and products Q1B. International Conference on Harmonization. Geneva, Switzerland: IFPMA; 1996.
- ICH. Stability testing for new dosage forms Q1C. International Conference on Harmonization. Geneva, Switzerland: IFPMA; 1996.
- ICH. Bracketing and matrixing designs for stability testing of new drug substances and products Q1D. International Conference on Harmonization. Geneva, Switzerland: IFPMA; 2002.
- ICH. Evaluation for stability data Q1E. International Conference on Harmonization. Geneva, Switzerland: IFPMA; 2003.
- Singh S, Junwal M, Modhe G, Tiwari H, Kurmi M, Parashar N, *et al.* Force degradation studies to assess the stability of drugs and products. *Trends Analyt Chem* 2013;49:71-88.

Archive of SID

16. Moein MM, El Beqqali A, Abdel-Rehim M. Bioanalytical method development and validation: Critical concepts and strategies. *J Chromatogr B Anal Technol Biomed Life Sci* 2017;1043:3-11.
17. Deshpande MM, Kasture VS, Mohan M, Chaudhari SR. Practical approach for development and validation of bioanalytical method: A review. *Inventi Rapid: Pharm Anal Qual Assur* 2017;2017:1-8.
18. Star VL, Hochberg MC. Prevention and management of gout. *US Nat Library Med* 1993;45:212-22.
19. Maher HM. Development and validation of a stability indicating HPLC-DAD method with an optimization for the determination of diflunisal and naproxen in pharmaceutical tablets. *J Liq Chromatogr Relat Technol* 2014;37:634-52.
20. Habib NM, Abdelwhab NS, Abdelrahman MM, Ali NW. Development and validation of chromatographic methods for resolving ternary mixture of diflunisal, naproxen and diflunisal toxic impurity. *Anal Chem Lett* 2015;5:399-409.
21. Reddy RS, Krishna RM, Vekaria NA, Sumathi RV, Mantena B. Determination of potential impurities of naproxen sodium in soft gelatin capsules dosage by using ultra performance liquid chromatography. *Anal Chem Lett* 2016;6:55-69.
22. Marwa AA, Ragab Eman I, EL-Kimary. High performance liquid chromatography with photo diode array for separation and analysis of naproxen and esomeprazole in presence of their chiral impurities: Enantiomeric purity determination in tablets. *J Chromatogr A* 2017;1497:110-7.
23. Kwong E, Pillai GK, McErlane KM. HPLC analysis of indomethacin and its impurities in capsule and suppository formulations. *J Pharm Sci* 1982;71:828-30.
24. Nováková L, Matysová L, Havlíková L, Solich P. Development and validation of HPLC method for determination of indomethacin and its two degradation products in topical gel. *J Pharm Biomed Anal* 2005;37:899-905.
25. Temussi F, Cermola F, Dellagrecia M, Iesce MR, Passananti M, Previtera L, *et al.* Determination of photostability and photodegradation products of indomethacin in aqueous media. *J Pharm Biomed Anal* 2011;56:678-83.
26. Haq N, Shakeel F, Ali M, Elbardy M, Alanazi FK, Alsarra IA. An environmentally benign approach for rapid analysis of indomethacin using stability indicating RP-HPLC method. *J Liq Chromatogr Relat Technol* 2014;37:878-92.
27. Bartsch H, Eiper A, Kopelent-Frank H. Stability indicating assays for the determination of piroxicam—Comparison of methods. *J Pharm Biomed Anal* 1999;20:531-41.
28. Hajkova R, Solich P, Pospisilova M, Sicha J. Simultaneous determination of methyl paraben, propyl paraben, sodium diclofenac and its degradation product in a topical emulgel by reversed-phase liquid chromatography. *Anal Chim Acta* 2002;467:91-6.
29. Galmier MJ, Bouchon B, Madelmont JC, Mercier F, Pilotaz F, Lartigue C. Identification of degradation products of diclofenac by electrospray ion trap mass spectrometry. *J Pharm Biomed Anal* 2005;38:790-6.
30. Krier F, Brion M, Debrus B, Lebrun P, Driesen A, Ziemons E, *et al.* Optimisation and validation of a fast HPLC method for the quantification of sulindac and its related impurities. *J Pharm Biomed Anal* 2011;54:694-700.
31. Hymer CB. Evaluation of an HPLC test for impurities in the corticosteroid, 11 β ,21-Dihydroxy-pregna-1,4-diene-3,20-dione[17a,16a-d]2'-methyloxazoline-21-acetate. *J Liq Chromatogr Relat Technol* 2004;27:1915-24.
32. Lu J, Wei Y, Rustum AM. A stability-indicating reversed-phase high performance liquid chromatography method for simultaneous assay of two corticosteroids and estimation of their related compounds in a pharmaceutical injectable formulation. *J Chromatogr A* 2010;1217:6932-41.
33. Marley A, Stalcup AM, Connolly D. Development and validation of a new stability indicating reversed phase liquid chromatographic method for the determination of prednisolone acetate and impurities in an ophthalmic suspension. *J Pharm Biomed Anal* 2015;102:261-6.
34. Matysová L, Hájková R, Sicha J, Solich P. Determination of methylparaben, propylparaben, triamcinolone acetonide and its degradation product in a topical cream by RP-HPLC. *Anal Bioanal Chem* 2003;376:440-3.
35. Kadivar MH, Sinha PK, Kushwah D, Jana P, Sharma H, Bapodra A. Study of impurity carryover and impurity profile in febuxostat drug substance by LC-MS/MS technique. *J Pharm Biomed Anal* 2011;56:749-57.
36. Loenhout JWA, Ginneken CAM, Ketelaars HCJ, Kimenai PM, Tan Y, Gribnau FWJ. A high-performance liquid chromatographic method for the quantitative determination of naproxen and des methyl-naproxen in biological samples. *J Liq Chromatogr* 1982;5:549-61.
37. Wanwimolruk S. A simple isocratic high performance liquid chromatographic determination of naproxen in human plasma using a microbore column technique. *J Liq Chromatogr* 1990;13:1611-25.
38. Karidas Th, Aygerinos A, Malamataris S. Extractionless HPLC method for the determination of naproxen in human plasma and urine. *Anal Lett* 1993;26:2341-8.
39. Mikami E, Goto T, Ohno T, Matsumoto H, Nishida M. Simultaneous analysis of naproxen, nabumetone and its major metabolite 6-methoxy-2-naphthylacetic acid in pharmaceuticals and human urine by high-performance liquid chromatography. *J Pharm Biomed Anal* 2000;23:917-25.
40. Elsinghorst PW, Kinzig M, Rodamer M, Holzgrabe U, Sörgel F. An LC-MS/MS procedure for the quantification of naproxen in human plasma: Development, validation, comparison with other methods, and application to a pharmacokinetic study. *J Chromatogr B* 2011;879:1686-96.
41. Patel DP, Sharma P, Sanyal M, Singhal P, Shrivastav PS. Challenges in the simultaneous quantitation of sumatriptan and naproxen in human plasma: application to a bioequivalence study. *J Chromatogr B* 2012;902:122-31.
42. Ahmadi F, Bapirzadeh T. High-performance liquid chromatographic determination of naproxen in plasma after extraction by a novel in-tube solid phase-liquid liquid extraction method. *J Liq Chromatogr Relat Technol* 2013;36:1280-95.
43. Shi X, Shang W, Wang S, Xue N, Hao Y, Wang Y, *et al.* Simultaneous quantification of naproxen and its active metabolite naproxen in rat plasma using LC-MS/MS: Application to a pharmacokinetic study. *J Chromatogr B* 2015;978-979:157-62.
44. Terweij-Groen CP, Heemstra S, Kraak JC. Rapid determination of indomethacin and salicylic acid in serum by means of reversed-phase liquid chromatography. *J Chromatogr B Biomed Sci Appl* 1980;181:385-97.
45. Bernstein MS, Evans MA. High-performance liquid chromatography-fluorescence analysis for indomethacin and metabolites in biological fluids. *J Chromatogr* 1982;229:179-87.
46. Shimek JL, Rao NGS, Wahba Khalil SK. High performance liquid chromatographic analysis of tolmetin, indomethacin and sulindac in plasma. *J Liq Chromatogr* 2006;4:1987-2013.
47. Greizerstein HB, McLaughlin IG. The rapid determination of indomethacin in 50 μ l blood samples. *J Liq Chromatogr* 2006;5:337-43.
48. Smith PC, Benet LZ. High-performance liquid chromatographic method for the determination of indomethacin and its two

Archive of SID

- primary metabolites in urine. *J Chromatogr B Biomed Sci Appl* 1984;306:315-21.
49. De Zeeuw D, Leinfelder JL, Brater DC. Highly sensitive measurement of indomethacin using a high-performance liquid chromatographic technique combined with post-column in-line hydrolysis. *J Chromatogr B Biomed Sci Appl* 1986;380:157-62.
50. Sauvaire D, Cociglio M, Alric R. Liquid chromatographic measurement for plasma indomethacin and its prodrug apyramide: Oral rat and intravenous dog pharmacokinetics. *J Chromatogr B Biomed Sci Appl* 1986;375:101-10.
51. Stubbs RJ, Schwartz MS, Chiou R, Entwistle LA, Bayne WF. Improved method for the determination of indomethacin in plasma and urine by reversed-phase high-performance liquid chromatography. *J Chromatogr B Biomed Sci Appl* 1986;383:432-37.
52. Brown YL, Kandrotas RJ, Douglas JB, Gal P. High-performance liquid chromatographic determination of indomethacin serum concentrations. *J Chromatogr* 1988;459:275-9.
53. Kim YI, El-harra S, Jun HW. Quantitation of indomethacin in serum by HPLC using fluorescence detection. *J Liq Chromatogr* 1988;11:3233-51.
54. Avgerinos A, Malamataris S. High-performance liquid chromatographic determination of indomethacin in human plasma and urine. *J Chromatogr B Biomed Sci Appl* 1989;495:309-13.
55. Hubert P, Renson M, Crommen J. A fully automated high-performance liquid chromatographic method for the determination of indomethacin in plasma. *J Pharm Biomed Anal* 1989;7:1819-27.
56. Mawatari KI, Linuma F, Watanabe M. Fluorimetric determination of indomethacin in human serum by high-performance liquid chromatography coupled with post-column photochemical reaction with hydrogen peroxide. *J Chromatogr B Biomed Sci Appl* 1989;491:389-96.
57. Singh AK, Jang Y, Mishra U, Granley K. Simultaneous analysis of flunixin, naproxen, ethacrynic acid, indomethacin, phenylbutazone, mefenamic acid and thiosalicylic acid in plasma and urine by high-performance liquid chromatography and gas chromatography-mass spectrometry. *J Chromatogr* 1991;568:351-61.
58. Caturla MC, Cusido E. Solid-phase extraction for the high-performance liquid chromatographic determination of indomethacin, suxibuzone, phenylbutazone and oxyphenbutazone in plasma, avoiding degradation of compounds. *J Chromatogr B Biomed Sci Appl* 1992;581:101-7.
59. Kubo H, Umiguchi Y, Kinoshita T. Fluorometric determination of indomethacin in serum by high performance liquid chromatography using in-line oxidation with hydrogen peroxide. *J Liq Chromatogr* 1993;16:465-74.
60. Vree TB, van den Biggelaar-Martea M, Verwey-van Wissen CP. Determination of indomethacin, its metabolites and their glucuronides in human plasma and urine by means of direct gradient high-performance liquid chromatographic analysis. Preliminary pharmacokinetics and effect of probenecid. *J Chromatogr B Biomed Sci Appl* 1993;616:271-82.
61. Niopas I, Mamzoridi K. Determination of indomethacin and mefenamic acid in plasma by high-performance liquid chromatography. *J Chromatogr B Biomed Sci Appl* 1994;656:447-50.
62. Sato J, Amizuka T, Niida Y, Umetsu M, Ito K. Simple, rapid and sensitive method for the determination of indomethacin in plasma by high-performance liquid chromatography with ultraviolet detection. *J Chromatogr B Biomed Sci Appl* 1997;692:241-4.
63. Liu S, Kamijo M, Takayasu T, Takayama S. Direct analysis of indomethacin in rat plasma using a column-switching high-performance liquid chromatographic system. *J Chromatogr B Analyt Technol* 2002;767:53-60.
64. Dawidowicz AL, Kondziola K, Kobielski M. Determination of free indomethacin in human plasma using HPLC with UV detection. *J Liq Chromatogr Relat Technol* 2009;32:2686-98.
65. Michail K, Moneeb MS. Determination of methotrexate and indomethacin in urine using SPE-LC-DAD after derivatization. *J Pharm Biomed Anal* 2011;55:317-24.
66. Liu Y, Guan F, Wang X, Zhang X, Di X. Development of a liquid chromatography-tandem mass spectrometry method for measuring plasma and uterine tissue levels of indomethacin in rabbits treated with indomethacin-medicated Cu-IUDs. *Contraception* 2012;85:419-24.
67. Wang X, Vernikovskaya DI, Nanovskaya TN, Rytting E, Hankins GD, Ahmed MS. A liquid chromatography method with single quadrupole mass spectrometry for quantitative determination of indomethacin in maternal plasma and urine of pregnant patients. *J Pharm Biomed Anal* 2013;78-79:123-8.
68. Twomey TM, Bartolucci SR, Hobbs DC. Analysis of piroxicam in plasma by high-performance liquid chromatography. *J Chromatogr B Biomed Sci Appl* 1980;183:104-8.
69. Dixon JS, Lowe JR, Galloway DB. Rapid method for the determination of either piroxicam or tenoxicam in plasma using high-performance liquid chromatography. *J Chromatogr B Biomed Sci Appl* 1984;310:455-9.
70. Richardson CJ, Ross SG. High-performance liquid chromatographic analysis of piroxicam and its major metabolite 5'-hydroxypiroxicam in human plasma and urine. *J Chromatogr B Biomed Sci Appl* 1986;382:382-8.
71. Macek J, Vacha J. Rapid and sensitive method for determination of piroxicam in human plasma by high-performance liquid chromatography. *J Chromatogr B Biomed Sci Appl* 1987;420:445-9.
72. Boudinot FD, Ibrahim SS. High-performance liquid chromatographic assay for piroxicam in human plasma. *J Chromatogr B Biomed Sci Appl* 1988;430:424-8.
73. Milligan PA. Determination of piroxicam and its major metabolites in the plasma, urine and bile of humans by high-performance liquid chromatography. *J Chromatogr B Biomed Sci Appl* 1992;576:121-8.
74. Cerretani D, Micheli L, Fiaschi AI, Giorgi G. Rapid and sensitive plasma, muscle and chromatography determination of piroxicam in rat skin by high-performance liquid. *J Chromatogr B Biomed Sci Appl* 1993;614:103-8.
75. Avgerinos A, Axarlis S, Dragatsis J, Karidas T, Malamataris S. Extractionless high-performance liquid chromatographic method for the simultaneous determination of piroxicam and 5'-hydroxypiroxicam in human plasma and urine. *J Chromatogr B Biomed Sci Appl* 1995;673:142-6.
76. Edno L, Bressolle F, Combe B, Galtier M. A reproducible and rapid HPLC assay for quantitation of piroxicam in plasma. *J Pharm Biomed Anal* 1995;13:785-9.
77. Maya MT, Pais JP, Morais JA. A rapid method for the determination of piroxicam in plasma by high-performance liquid chromatography. *J Pharm Biomed Anal* 1995;13:319-22.
78. Amanlou M, Dehpour AR. Rapid method for the determination of piroxicam in rat plasma using high-performance liquid chromatography. *J Chromatogr B Biomed Sci Appl* 1997;696:317-9.
79. Yritia M, Parra P, Fernández JM, Barbanoj JM. Piroxicam quantitation in human plasma by high-performance liquid

Archive of SID

- chromatography with on- and off-line solid-phase extraction. *J Chromatogr A* 1999;846:199-205.
80. Dadashzadeh S, Vali AM, Rezagholi N. LC determination of piroxicam in human plasma. *J Pharm Biomed Anal* 2002;28:1201-4.
81. Ji HY, Lee HW, Kim YH, Jeong DW, Lee HS. Simultaneous determination of piroxicam, meloxicam and tenoxicam in human plasma by liquid chromatography with tandem mass spectrometry. *J Chromatogr B Analyt Technol B* 2005;826:214-9.
82. Dowling G, Malone E. Analytical strategy for the confirmatory analysis of the non-steroidal anti-inflammatory drugs firocoxib, propyphenazone, ramifenazone and piroxicam in bovine plasma by liquid chromatography tandem mass spectrometry. *J Pharm Biomed Anal* 2011;56:359-65.
83. Calvo AM, Santos GM, Dionísio TJ, Marques MP, Brozowski DT, Lanchote VL, *et al.* Quantification of piroxicam and 5'-hydroxy-piroxicam in human plasma and saliva using liquid chromatography-tandem mass spectrometry following oral administration. *J Pharm Biomed Anal* 2016;120:212-20.
84. Godbillon J, Gauron S, Metayer JP. High-performance liquid chromatographic determination of diclofenac and its monohydroxylated metabolites in biological fluids. *J Chromatogr B Biomed Sci Appl* 1985;338:151-9.
85. Sioufi A, Richard J, Mangoni P, Godbillon J. Determination of diclofenac in plasma using a fully automated analytical system combining liquid-solid extraction with liquid chromatography. *J Chromatogr B Biomed Sci Appl* 1991;565:401-7.
86. Moncrieff J. Extractionless determination of diclofenac sodium in serum using reversed-phase high-performance liquid chromatography with fluorimetric detection. *J Chromatogr B Biomed Sci Appl* 1992;577:185-9.
87. Blagbrough IS, Daykin MM. High-performance liquid chromatographic determination of naproxen, ibuprofen and diclofenac in plasma and synovial fluid in man. *J Chromatogr B Biomed Sci Appl* 1992;578:251-7.
88. Miller RB. High-performance liquid chromatographic determination of diclofenac in human plasma using automated column switching. *J Chromatogr B Biomed Sci Appl* 1993;616:283-90.
89. Avgerinos A, Karidas T, Malamataris S. Extractionless high-performance liquid chromatographic method for the determination of diclofenac in human plasma and urine. *J Chromatogr B Biomed Sci Appl* 1993;619:324-9.
90. Mohamed FA, Jun HW, Elfaham TH, Sayed HA, Hafez E. An improved HPLC procedure for the quantitation of diclofenac in plasma. *J Liq Chromatogr* 1994;17:1065-88.
91. Mason JL, Hobbs GJ. A rapid high performance liquid chromatographic assay for the measurement of diclofenac in human plasma. *J Liq Chromatogr* 1995;18:2045-58.
92. Li K, Zhao FL, Yuan YS, Tan L. Determination of diclofenac sodium in human plasma by reversed-phase liquid chromatography. *J Liq Chromatogr* 1995;18:2205-16.
93. Kuhlmann O, Stoldt G, Struck HG, Krauss GJ. Simultaneous determination of diclofenac and oxybuprocaine in human aqueous humor with HPLC and electrochemical detection. *J Pharm Biomed Anal* 1998;17:1351-6.
94. Giagoudakis G, Markantonis SL. An alternative high-performance liquid chromatographic method for the determination of diclofenac and flurbiprofen in plasma. *J Pharm Biomed Anal* 1998;868:64-9.
95. Bakkali A, Corta E, Berrueta LA, Gallo B, Vicente F. Study of the solid-phase extraction of diclofenac sodium, indomethacin and phenylbutazone for their analysis in human urine by liquid chromatography. *J Chromatogr B Biomed Sci Appl* 1999;729:139-45.
96. Lee HS, Jeong CK, Choi SJ, Kim SB, Lee MH, Ko GI, *et al.* Simultaneous determination of aceclofenac and diclofenac in human plasma by narrowbore HPLC using column-switching. *J Pharm Biomed Anal* 2000;23:775-81.
97. Arcelloni C, Lanzi R, Pedercini S, Molteni G, Fermo I, Pontiroli A, *et al.* High-performance liquid chromatographic determination of diclofenac in human plasma after solid-phase extraction. *J Chromatogr B Biomed Sci Appl* 2001;763:195-200.
98. Liu SC, Tsai TH. Determination of diclofenac in rat bile and its interaction with cyclosporin A using on-line microdialysis coupled to liquid chromatography. *J Chromatogr B* 2002;769:351-6.
99. Dorado P, Berecz R, Cáceres MC, LLerena A. Analysis of diclofenac and its metabolites by high-performance liquid chromatography: Relevance of CYP2C9 genotypes in diclofenac urinary metabolic ratios. *J Chromatogr B* 2003;789:437-42.
100. Roskar R, Kmetec V. Liquid chromatographic determination of diclofenac in human synovial fluid. *J Chromatogr B* 2003;788:57-64.
101. Malliou ET, Markopoulou CK, Koundourellis JE. Simultaneous determination of clobutinol together with some anti-inflammatory drugs in urine by HPLC. *J Liq Chromatogr Relat Technol* 2004;27:1565-77.
102. Kaphalia L, Kaphalia BS, Kumar S, Kanz MF, Treinen-Moslen M. Efficient high performance liquid chromatograph/ultraviolet method for determination of diclofenac and 4'-hydroxydiclofenac in rat serum. *J Chromatogr B* 2006;830:231-7.
103. Sparidans RW, Lagas JS, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for diclofenac and three primary metabolites in mouse plasma. *J Chromatogr B* 2008;872:77-82.
104. Nasir F, Iqbal Z, Khan A, Ahmad L, Shah Y, Khan AZ, *et al.* Simultaneous determination of timolol maleate, rosuvastatin calcium and diclofenac sodium in pharmaceuticals and physiological fluids using HPLC-UV. *J Chromatogr B* 2011;879:3434-43.
105. Aguiar FA, Malvar DDC, Kanashiro A, Seoane MF, Cuffini SL, Souza GEP, *et al.* Determination of diclofenac sodium in rabbit plasma by HPLC/UV: Evaluation and characterization of its crystalline forms, anhydrous and hydrate, on the antipyretic effect. *J Liq Chromatogr Relat Technol* 2012;35:2408-24.
106. Emara LH, Taha NF, El-Ashmawy AA, Raslan HM, Mursi NM. A rapid and sensitive bioanalytical HPLC method for determining diclofenac sodium in human plasma for bioequivalence studies. *J Liq Chromatogr Relat Technol* 2012;35:2203-16.
107. Pound NJ, Sears RW. Simultaneous determination of phenylbutazone and oxyphenbutazone in plasma by high-speed liquid chromatography. *J Pharm Sci* 1975;64:284-7.
108. Marunaka T, Shibata T, Minami Y, Umeno Y. Simultaneous determination of phenylbutazone and its metabolites in plasma and urine by high-performance liquid chromatography. *J Chromatogr B Biomed Sci Appl* 1980;183:331-8.
109. Hardee GE, Lai JW, Moore JN. Simultaneous determination of flunixin, phenylbutazone, oxyphenbutazone and γ -hydroxyphenylbutazone in equine plasma by high-performance liquid chromatography with application to pharmacokinetics. *J Liq Chromatogr* 1982;5:1991-2003.
110. Taylor MR, Westwood SA. Quantitation of phenylbutazone and oxyphenbutazone in equine plasma by high-performance liquid chromatography with solid-phase extraction. *J Chromatogr A* 1995;697:389-96.
111. Neto LM, Andraus MH, Salvadori MC. Determination of phenylbutazone and oxyphenbutazone in plasma and urine samples of horses by high-performance liquid chromatography and gas chromatography-mass spectrometry. *J Chromatogr B Biomed Appl* 1996;678:211-8.

Archive of SID

112. Haque A, Stewart JT. Direct injection HPLC method for the determination of phenylbutazone and oxyphenylbutazone in serum using a semipermeable surface column. *J Pharm Biomed Anal* 1997;16:287-93.
113. Grippa E, Santini L, Castellano G, Gatto MT, Leone MG, Saso L. Simultaneous determination of hydrocortisone, dexamethasone, indomethacin, phenylbutazone and oxyphenylbutazone in equine serum by high-performance liquid chromatography. *J Chromatogr B Biomed Sci Appl* 2000;738:17-25.
114. Asea PEA, Souster KD, Salisbury CDC, Boison JO. Development and validation of a method for the determination of phenylbutazone drug residues in bovine, equine, and porcine muscle tissues using HPLC with UV detection. *J Liq Chromatogr Relat Technol* 2004;27:3013-27.
115. Igualada C, Moragues F. Determination of phenylbutazone and oxyphenylbutazone in animal urine by ion trap liquid chromatography–mass spectrometry. *Anal Chim Acta* 2005;529:235-8.
116. Sioufi A, Colussi D, Mangoni P. Determination of oxyphenylbutazone in human plasma by high-performance liquid chromatography. *J Chromatogr B Biomed Sci Appl* 1983;275:201-5.
117. Swanson BN, Boppana VK. Measurement of sulindac and its metabolites in human plasma and urine by high-performance liquid chromatography. *J Chromatogr B Biomed Sci Appl* 1981;225:123-30.
118. Grgurinovich N. High-performance liquid chromatography of sulindac and its sulphone and sulphide metabolites in plasma. *J Chromatogr B Biomed Sci Appl* 1987;414:211-6.
119. Ray GF, Lanman RC, Fu CJ, Paranka NS, Pamukcu R, Wheeler SC. Determination of FGN-1 (an active metabolite of sulindac) in human plasma, urine, and feces by HPLC. *J Pharm Biomed Anal* 1995;14:213-20.
120. Fluri K, Rivier L, Dienes-Nagy A, You C, Maître A, Schweizer C, *et al.* Method for confirmation of synthetic corticosteroids in doping urine samples by liquid chromatography–electrospray ionisation mass spectrometry. *J Chromatogr A* 2001;926:87-95.
121. Sangiorgi E, Curatolo M, Assini W, Bozzoni E. Application of neutral loss mode in liquid chromatography–mass spectrometry for the determination of corticosteroids in bovine urine. *Anal Chim Acta* 2003;483:259-67.
122. Rönquist-Nii Y, Edlund PO. Determination of corticosteroids in tissue samples by liquid chromatography–tandem mass spectrometry. *J Pharm Biomed Anal* 2005;37:341-50.
123. Leung GN, Chung EW, Ho EN, Kwok WH, Leung DK, Tang FP, *et al.* High-throughput screening of corticosteroids and basic drugs in horse urine by liquid chromatography–tandem mass spectrometry. *J Chromatogr B* 2005;825:47-56.
124. Spyridaki MH, Kiouisi P, Vonaparti A, Valavani P, Zonaras V, Zahariou M, *et al.* Doping control analysis in human urine by liquid chromatography–electrospray ionization ion trap mass spectrometry for the Olympic Games Athens 2004: Determination of corticosteroids and quantification of ephedrine, salbutamol and morphine. *Anal Chim Acta* 2006;573-574:242-9.
125. Ho ENM, Leung DKK, Wan TSM, Yu NH. Comprehensive screening of anabolic steroids, corticosteroids, and acidic drugs in horse urine by solid-phase extraction and liquid chromatography–mass spectrometry. *J Chromatogr A* 2006;1120:38-53.
126. Cho HJ, Kim JD, Lee WY, Chung BC, Choi MH. Quantitative metabolic profiling of 21 endogenous corticosteroids in urine by liquid chromatography–triple quadrupole–mass spectrometry. *Anal Chim Acta* 2009;632:101-8.
127. Andersen JH, Hansen LG, Pedersen M. Optimization of solid phase extraction clean up and validation of quantitative determination of corticosteroids in urine by liquid chromatography–tandem mass spectrometry. *Anal Chim Acta* 2008;617:216-24.
128. Gao L, Chiou WJ, Camp HS, Burns DJ, Cheng X. Quantitative measurements of corticosteroids in *ex vivo* samples using on-line SPE-LC/MS/MS. *J Chromatogr B* 2009;877:303-10.
129. Croes K, Goeyens L, Baeyens W, Van Loco J, Impens S. Optimization and validation of a liquid chromatography tandem mass spectrometry (LC/MSn) method for analysis of corticosteroids in bovine liver: Evaluation of keyhole Limpet beta-glucuronidase/sulfatase enzyme extract. *J Chromatogr B* 2009;877:635-44.
130. Dusi G, Gasparini M, Curatolo M, Assini W, Bozzoni E, Tognoli N, *et al.* Development and validation of a liquid chromatography–tandem mass spectrometry method for the simultaneous determination of nine corticosteroid residues in bovine liver samples. *Anal Chim Acta* 2011;700:49-57.
131. Deceuninck Y, Bichon E, Monteau F, Antignac JP, Le Bizec B. Determination of MRL regulated corticosteroids in liver from various species using ultra high performance liquid chromatography–tandem mass spectrometry (UHPLC). *Anal Chim Acta* 2011;700:137-43.
132. Pavlovic R, Chiesa L, Soncin S, Panseri S, Cannizzo FT, Biolatti B, *et al.* Determination of cortisol, cortisone, prednisolone and prednisone in bovine urine by liquid chromatography–electrospray ionisation single quadrupole mass spectrometry. *J Liq Chromatogr Relat Technol* 2012;35:444-57.
133. Marcos J, Renau N, Casals G, Segura J, Ventura R, Pozo OJ. Investigation of endogenous corticosteroids profiles in human urine based on liquid chromatography tandem mass spectrometry. *Anal Chim Acta* 2014;812:92-104.
134. Rey-Salgueiro L, Martínez-Carballo E, Simal-Gándara J. Liquid chromatography–mass spectrometry method development for monitoring stress-related corticosteroids levels in pig saliva. *J Chromatogr B* 2015;990:158-63.
135. Loo JC, Butterfield AG, Moffatt J, Jordan N. Analysis of prednisolone in plasma by high-performance liquid chromatography. *J Chromatogr B Biomed Sci Appl* 1977;143:275-80.
136. Frey BM, Frey FJ. Simultaneous measurement of prednisone, prednisolone and 6 beta-hydroxyprednisolone in urine by high-performance liquid chromatography coupled with a radioactivity detector. *J Chromatogr B Biomed Sci Appl* 1982;29:283-92.
137. Ui T, Mitsunaga M, Tanaka T, Horiguchi M. Determination of prednisone and prednisolone in human serum by high-performance liquid chromatography—Especially on impaired conversion of corticosteroids in patients with chronic liver disease. *J Chromatogr* 1982;239:711-6.
138. Prasad VK, Ho B, Haneke C. Simultaneous determination of prednisolone acetate, prednisolone, prednisone, cortisone and hydrocortisone in swine plasma using solid-phase and liquid-liquid extraction techniques. *J Chromatogr B Biomed Sci Appl* 1986;378:305-16.
139. Carlin AS, Prasad VK, Sager AO, Simmons JE, Skelly JP. Analysis of prednisolone acetate and related corticoids in swine plasma by reversed-phase high-performance liquid chromatography. *J Chromatogr B Biomed Sci Appl* 1988;425:162-8.
140. Yamaguchi M, Ishida J, Yoshitake T, Nakamura M. Determination of prednisolone and prednisone in plasma by liquid chromatography with fluorescence detection. *Anal Chim Acta* 1991;242:113-6.
141. Musson DG, Bidgood AM, Olejnik O. Assay methodology for prednisolone, prednisolone acetate and prednisolone sodium phosphate in rabbit aqueous humor and ocular physiological solutions. *J Chromatogr B Biomed Sci Appl* 1991;565:89-102.

Archive of SID

142. Garg V, Jusko WJ. Simultaneous analysis of prednisone, prednisolone and their major hydroxylated metabolites in urine by high-performance liquid chromatography. *J Chromatogr B Biomed Sci Appl* 1991;567:39-47.
143. Jusko WJ, Pyszczyński NA, Bushway MS, D'Ambrosio R, Mis SM. Fifteen years of operation of a high-performance liquid chromatographic assay for prednisolone, cortisol and prednisone in plasma. *J Chromatogr B Biomed Appl* 1994;658:47-54.
144. Hirata H, Kasama T, Sawai Y, Fike RR. Simultaneous determination of deflazacort metabolites II and III, cortisol, cortisone, prednisolone and prednisone in human serum by reversed-phase high-performance liquid chromatography. *J Chromatogr B Biomed Appl* 1994;658:55-61.
145. Döppenschmitt SA, Scheidel B, Harrison F, Surmann JP. Simultaneous determination of prednisolone, prednisolone acetate and hydrocortisone in human serum by high-performance liquid chromatography. *J Chromatogr B Biomed Appl* 1995;674:237-46.
146. AbuRuz S, Millership J, Heaney L, McElnay J. Simple liquid chromatography method for the rapid simultaneous determination of prednisolone and cortisol in plasma and urine using hydrophilic lipophilic balanced solid phase extraction cartridges. *J Chromatogr B* 2003;798:193-201.
147. Frerichs VA, Tornatore KM. Determination of the glucocorticoids prednisone, prednisolone, dexamethasone, and cortisol in human serum using liquid chromatography coupled to tandem mass spectrometry. *J Chromatogr B* 2004;802:329-38.
148. Difrancesco R, Frerichs V, Donnelly J, Hagler C, Hochreiter J, Tornatore KM. Simultaneous determination of cortisol, dexamethasone, methylprednisolone, prednisone, prednisolone, mycophenolic acid and mycophenolic acid glucuronide in human plasma utilizing liquid chromatography-tandem mass spectrometry. *J Chromatogr B* 2007;859:42-51.
149. Ding X, Rose MJ, McCaffery I, Rossi J, Paweletz K, Hale C, *et al.* Determination of prednisolone in human adipose tissue incubation medium using LC-MS/MS to support the measurement of 11 β -hydroxysteroid dehydrogenase activity. *J Chromatogr B* 2009;877:1394-401.
150. Chen M, Granvil C, Ji QC, Zhang ZY, Padval MV, Kansra VV. Development and validation of a liquid chromatography-tandem mass spectrometry assay for the simultaneous quantitation of prednisolone and dipyrindamole in human plasma and its application in a pharmacokinetic study. *J Pharm Biomed Anal* 2009;49:1241-9.
151. Ionita IA, Fast DM, Akhlaghi F. Development of a sensitive and selective method for the quantitative analysis of cortisol, cortisone, prednisolone and prednisone in human plasma. *J Chromatogr B* 2009;877:765-72.
152. McWhinney BC, Briscoe SE, Ungerer JP, Pretorius CJ. Measurement of cortisol, cortisone, prednisolone, dexamethasone and 11-deoxycortisol with ultra high performance liquid chromatography-tandem mass spectrometry: Application for plasma, plasma ultrafiltrate, urine and saliva in a routine laboratory. *J Chromatogr B* 2010;878:2863-9.
153. Fung EN, Xia YQ, Aubry AF, Zeng J, Olah T, Jemal M. Full-scan high resolution accurate mass spectrometry (HRMS) in regulated bioanalysis: LC-HRMS for the quantitation of prednisone and prednisolone in human plasma. *J Chromatogr B* 2011;879:2919-27.
154. Li H, Xia X, Xue Y, Tang S, Xiao X, Li J, *et al.* Simultaneous determination of amoxicillin and prednisolone in bovine milk using ultra-high performance liquid chromatography tandem mass spectrometry. *J Chromatogr B* 2012;900:59-63.
155. Liu Y, Zhu K, Wang J, Huang X, Wang G, Li C, *et al.* Simultaneous detection and comparative pharmacokinetics of amoxicillin, clavulanic acid and prednisolone in cows' milk by UPLC-MS/MS. *J Chromatogr B* 2016;1008:74-80.
156. Huang Y, Bo Y, Wu X, Wang Q, Qin F, Zhao L, *et al.* An integrated serum and urinary metabolomic research based on UPLC-MS and therapeutic effects of Gushudan on prednisolone-induced osteoporosis rats. *J Chromatogr B* 2016;1027:119-30.
157. Döppenschmitt SA, Scheidel B, Harrison F, Surmann JP. Simultaneous determination of triamcinolone acetonide and hydrocortisone in human plasma by high-performance liquid chromatography. *J Chromatogr B Biomed Appl* 1996;682:79-88.
158. Głowska FK, Karaźniewicz M, Lipnicka E. RP-HPLC method with fluorescence detection for determination of small quantities of triamcinolone in plasma in presence of endogenous steroids after derivatization with 9-anthroyl nitrile; pharmacokinetic studies. *J Chromatogr B* 2006;839:54-61.
159. Vieira MdeL, Singh RP, Derendorf H. Simultaneous HPLC analysis of triamcinolone acetonide and budesonide in microdialysate and rat plasma: Application to a pharmacokinetic study. *J Chromatogr B* 2010;878:2967-73.
160. Jiang Y, Wang J, Wang Y, Li H, Fawcett JP, Gu J. Rapid and sensitive liquid chromatography-tandem mass spectrometry method for the quantitation of colchicine in human plasma. *J Chromatogr B* 2007;850:564-8.
161. Chen QH, Hou S, Gan LC, Li YB, Song X, Cai Z. Determination of colchicine in mouse plasma by high performance liquid-chromatographic method with UV detection and its application to pharmacokinetic studies. *Pharm Soc Japan* 2007;127:1485-90.
162. Bourgogne E, Soichot M, Latour C, Laprévote O. Rugged and accurate quantitation of colchicine in human plasma to support colchicine poisoning monitoring by using turbulent-flow LC-MS/MS analysis. *Future Sci* 2013;5:2889-96.
163. Kovasu SP, Kunamaneni P, Yeung S, Kodali B. Determination of colchicine in human plasma by a sensitive LC-MS/MS assay. *World J Pharm Pharm Sci* 2018;7:35-44.
164. Inaba T, Besley ME, Chow EJ. Determination of sulfinpyrazone in serum by high-performance liquid chromatography. *J Chromatogr* 1975;104:165-9.
165. Wong LT, Solomonraj G, Thomas BH. Simple and rapid micro-determination of sulfinpyrazone (Anturan) in biological fluids by reversed-phase high-performance liquid chromatography. *J Chromatogr* 1978;150:521-6.
166. Björnsson TD, Wolfram KM, Routledge PA, Shand DG. High-performance liquid chromatographic analysis of sulfinpyrazone and its metabolites in biological fluids. *J Chromatogr B Biomed Sci Appl* 1980;181:417-25.
167. Jakobsen P, Pedersen AK. Simultaneous determination of sulfinpyrazone and four of its metabolites by high-performance liquid chromatography. *J Chromatogr B Biomed Sci Appl* 1981;223:460-5.
168. Godbillon J, Gauron S, Gosset G. High-performance liquid chromatographic analysis of the sulfide metabolite of sulfinpyrazone in plasma. *J Chromatogr B Biomed Sci Appl* 1982;227:516-20.
169. de Vries JX, Staiger C, Wang NS, Schlicht F. Analysis of sulfinpyrazone and its metabolites in human plasma and urine by high-performance liquid chromatography. *J Chromatogr B Biomed Sci Appl* 1983;277:408-13.
170. Tam YK, Ferguson SM, Yau ML, Wyse DG. Simple and rapid high-performance liquid chromatographic method for the analysis of sulfinpyrazone and four of its metabolites in human plasma. *J Chromatogr B Biomed Sci Appl* 1984;310:438-44.
171. Vergin H, Bishop G. High-performance liquid chromatographic determination of benzbromarone and the main metabolite benzarone in serum. *J Chromatogr B Biomed Sci Appl* 1980;183:383-6.
172. Arnold PJ, Guserle R, Luckow V, Hemmer R, Grote H. Liquid chromatography-mass spectrometry in metabolic research.

Archive of SID

- I. Metabolites of benzbromarone in human plasma and urine. *J Chromatogr* 1991;554:267-80.
173. Wu H, Peng Y, Wang S, Wang K, Zhao X, Jiang F. Metabolism studies of benzbromarone in rats by high performance liquid chromatography-quadrupole time of flight mass spectrometry. *J Chromatogr B* 2012;911:122-32.
174. Wang H, Deng P, Chen X, Guo L, Zhong D. Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of Febuxostat in human plasma. *Biomed Chromatogr* 2013;27:34-8.
175. Vaka VRM, Inamadugu JK, Pilli NR, Ramesh M, Katreddi HR. A sensitive LC-MS/MS method for the quantification of febuxostat in human plasma and its pharmacokinetic application. *Biomed Chromatogr* 2013;27:1406-12.
176. Chandu BR, Kanala K, Hwisa NT, Katakam P, Khagga M. Bioequivalence and pharmacokinetic study of febuxostat in human plasma by using LC-MS/MS with liquid liquid extraction method. *Springer* 2013;2:1-10.
177. Xie H, Wang Z, Deng K, Jiang X, Wang L, Lv G. An HPLC-MS/MS method for simultaneous determination of the active metabolites of febuxostat (67M-1, 67M-2 and 67M-4) in human plasma. *J Chromatogr B* 2014;970:24-30.
178. Choudhury H, Gorain B, Das A, Ghosh B, Pal T. Development and validation of a sensitive HPLC-MS/MS-ESI method for determination of Febuxostat: Application to pharmacokinetic study. *Curr Anal Chem* 2014;10:528-36.
179. Wu Y, Mao Z, Liu Y, Wang X, Di X. Simultaneous determination of febuxostat and its three active metabolites in human plasma by liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study in Chinese healthy volunteers. *J Pharm Biomed Anal* 2015;114:216-21.
180. Reinders MK, Nijdam LC, van Roon EN, Movig KL, Jansen TL, van de Laar MA, *et al.* A simple method for quantification of allopurinol and oxipurinol in human serum by high-performance liquid chromatography with UV-detection. *J Pharm Biomed Anal* 2007;45:312-7.
181. Kasawar G, Razzak M, Zaheer Z, Farooqui M. Validated RP-LC-MS/MS method for the simultaneous determination of allopurinol and its major metabolite, oxypurinol, in human plasma. *J Liq Chromatogr Relat Technol* 2010;34:26-37.
182. Liu X, Ni XJ, Shang DW, Zhang M, Hu JQ, Qiu C, *et al.* Determination of allopurinol and oxypurinol in human plasma and urine by liquid chromatography-tandem mass spectrometry. *J Chromatogr B* 2013;941:10-6.
183. Rathod DM, Patel KR, Mistri HN, Jangid AG, Shrivastav PS, Sanyal M. Simultaneous analysis of allopurinol and oxypurinol using a validated liquid chromatography-tandem mass spectrometry method in human plasma. *J Pharm Anal* 2017;7: 56-62.